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ABSTRACT 
Cardiovascular disease is the main cause of death in the world. The underlying cause in most 
cases is atherosclerosis, a chronic inflammatory disease. Subendothelial retention of 
lipoproteins triggers monocyte-derived macrophages and T-helper (Th) 1 cells to form lipid-
laden atherosclerotic plaques in the artery wall. The Th1 cells react to autoantigens from the 
ApoB protein in low-density lipoprotein (LDL) perpetuating the inflammation initiated by the 
innate immune reactions to modified lipoproteins. Other T-helper cells are also active in the 
lesions with regulatory T cells (Treg) limiting the injurious inflammation, while the effects of 
Th17 cells are less clear. 
The slow build-up of atherosclerotic plaques is asymptomatic, but eventually the plaque may 
cause symptoms. Plaque rupture or endothelial erosion induces thrombus formation that 
causes a heart attack or ischemic stroke. Advanced plaques usually contain large cholesterol-
rich necrotic cores. This determines plaque stability along with a stable cap formation by 
smooth muscle cells and collagen. Prevention of risk factors has reduced mortality, but there 
is still a need for novel therapies to stabilize plaques and to treat arterial inflammation. The 
aim for this thesis is to investigate T-cell responses to LDL and regulation of Th cells during 
atherogenesis. Genetically modified mouse models were used to study LDL-reactive T cells, 
mechanisms involved in Th cell differentiation, and the subsequent influence on disease 
development. 
Paper I shows how inflammatory signals from the atherosclerotic lesions contribute to Th17 
cell differentiation by means of IL-6 and transforming growth factor  (TGF-. Th17 cells 
produce IL-17A that promotes collagen synthesis by smooth muscle cells. This paper 
establishes a plaque-stabilizing role for Th17 cells and IL-17A, which is likely to operate in 
man and reduce incidence of myocardial infarctions. 
Paper II establishes that Tregs have a protective role in atherosclerosis by modulating lipid 
metabolism. Depletion of Foxp3+ Tregs during atherogenesis impairs lipoprotein uptake by 
unleashing liver inflammation that downregulates the very low-density lipoprotein (VLDL)-
regulating protein called sortilin. This leads to increased plasma cholesterol and development 
of large atherosclerotic plaques with lipid-filled necrotic cores. 
Paper III shows how LDL-reactive T cells survive clonal selection in the thymus, 
differentiate into T follicular helper cells (Tfh), and promote a protective B-cell response with 
anti-LDL antibodies. These antibodies mediate lipoprotein clearance and lower plasma 
cholesterol, which protects against atherosclerosis. 
All three papers presented in this thesis illustrate an intricate interplay between the immune 
system and lipoprotein metabolism, resulting in profound effects on atherosclerosis. These 
notions may lead to new therapies that stabilize atherosclerotic plaques through specific anti-
inflammatory actions that are mirrored by lipid-lowering effects. 
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
The immune system protects us against foreign pathogens such as bacteria, viruses, parasites, 
and fungi [1]. When an infection occurs, the immune system fights the pathogen and clears 
the infection. A hallmark of immunity is a specific memory that distinguishes self from non-
self. The basis for this is antigen recognition. Physical and chemical barriers prevent potential 
pathogens from entering through the skin, lungs, and gut. Cells in these locations take an 
active part in the defense before the immune system is engaged and secrete antimicrobial 
peptides, produce mucus, and have cilia that impede infections. In addition, commensal 
bacteria exist in concordance with the host and prevent pathogens to take foothold [2].  
The immune system is commonly divided into an innate and an adaptive part. The innate 
system is fast, but unspecific and calls for the attention of the slower adaptive system that is 
specific. The two systems communicate with cell-to-cell interactions and soluble molecules 
such as chemokines and cytokines. Activation of the immune system leads to inflammation. 
In the 1st century, Celsus described four signs of inflammation: calor, dolor, rubor, and tumor 
(heat, pain, redness, and swelling) [3]. Later, functio laesa, the disturbance of function, was 
added as a fifth cardinal sign of inflammation [4]. Apart from infections, the immune system 
has an important function to maintain host homeostasis through tissue repair and tumor 
surveillance. When the infection is cleared, inflammation resolves by regulatory mechanisms, 
one being wound-healing [5]. 
1.1.1 The innate immune system 
The innate immune system recognizes common characteristics of pathogens [6]. This defense 
system is particularly present at sites where pathogens are expected, allowing a fast response 
to take place instantly when a pathogen eludes the first line of barrier defense. The innate 
immune system relies on pattern recognition receptors (PRR). These receptors are germ-line 
encoded and recognize pathogen-associated molecular patterns. Toll like receptors (TLR) on 
innate immune cells are PRRs that convey one of the first signals that start the immune 
response. These receptors belong to the most evolutionarily conserved and ancient part of the 
immune system [7]. Some TLRs recognize extracellular components of bacteria, such as 
lipopolysaccharides. Other TLRs are intracellular and control the endolysosomal 
compartment for invading viruses or intracellular bacteria [8]. Scavenger receptors are 
extracellular PRRs that recognize foreign material and initiate its internalization and 
destruction [9]. These receptors also take part in housekeeping duties in the body, such as 
clearing modified lipoproteins. 
Soluble PRRs circulate in the blood as part of the complement system. These proteins are 
ready to directly lyse cells or activate cellular components of the innate system [10]. This 
network of proteins recognizes pathogen surfaces. A reaction cascade forms complexes that 
attack and puncture the membrane of pathogens. The complement system also facilitates 
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phagocytosis of bacteria by opsonization [11], activates inflammatory responses, and helps in 
clearing immune complexes that consist of antibodies bound to antigen. 
Main cellular components of the innate immune system are monocytes, macrophages, 
granulocytes, mast cells, dendritic cells, and innate lymphoid cells. Monocytes and neutrophil 
granulocytes are phagocytic cells that are rapidly recruited to the site of infection. The initial 
inflammatory response consists of extravasation mediated by IL-1, tumor necrosis factor 
(TNF), and chemokines [12]. Endothelial cells upregulate adhesion molecules and circulating 
neutrophils and monocytes adhere to the endothelial surface and infiltrate the underlying 
tissue. Chemoattractants guide the infiltrating cells to the site of infection where the pathogen 
is attacked and ingested by phagocytosis [13]. The monocytes differentiate into macrophages 
after entering the tissue. Mast cells share common characteristics with basophil granulocytes, 
but reside locally in tissues close to potential infection sites. They express FcεRI receptors 
with high affinity for Immunoglobulin E (IgE) antibodies. IgE therefore coats mast cells. 
When antigen-specific IgE on the mast cell surface cross-links an antigen, a signal through 
FcεRI leads to degranulation and release of histamine as well as other pro-inflammatory 
mediators and enzymes. This occurs in a common allergic reaction when IgE antibodies are 
directed against an allergen [14]. 
Dendritic cells are professional antigen presenters and specialized in internalizing foreign 
antigens [15]. They patrol the tissue and take up potential pathogens that are then degraded in 
the phagolysosome and presented to T cells after migration to lymph nodes and spleen. Also 
macrophages act as antigen presenting cells (APC) and express MHC class II. Dendritic cells 
can be divided into three subgroups: classical, plasmacytoid, and monocyte-derived. 
Plasmacytoid dendritic cells are a rare subset that produce large amounts of type I interferons 
(IFN-/), which are important during virus infections [16]. 
Natural killer cells belong to the innate lymphoid cell family and are cytotoxic effector cells 
important for tumor surveillance and fighting viruses [17]. They identify and kill cells that 
have downregulated MHC class I to evade regular immune surveillance [18]. Other innate-
like lymphocytes are B1 cells, marginal zone B cells,  T cells, and natural killer T cells. 
These cells resemble adaptive immune cells, but usually reside in special compartments of 
the body ready to recognize and neutralize antigens or evoke immune reactions. The 
specificities of B1 cells and natural killer T cells are largely against evolutionary preserved 
antigens in pathogens, such as complex lipids [19]. 
1.1.2 The adaptive immune system 
The adaptive immune system acquires immunity against pathogens and remembers this initial 
recognition for later encounters with the same pathogen. It is called upon when the innate 
system is incapable of handling the intruding pathogen alone. The adaptive response requires 
gene rearrangements that store the antigen specificity within the genetic code. This makes the 
system slow with a response peak usually one or two weeks after the first encounter with a 
foreign pathogen, but memory makes the time shorter the next time the host encounters the 
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same pathogen. The secondary immune response is much faster, and the pathogen is usually 
handled before general symptoms arise. 
The adaptive immune system consists of lymphocytes developed from progenitor cells in the 
bone marrow. These cells carry either T-cell receptors (TCR) or B-cell receptors (BCR), 
which are epitope-specific antigen receptors. T cells with TCRs are the basis for the cellular 
immunity [20], and B cells with BCRs that can be secreted as antibodies, form the humoral 
immunity. T and B cells interact in an antigen-specific manner [21]. This potent system needs 
to be tightly controlled in order to avoid excessive tissue destruction when fighting an 
infection. The specificity of the lymphocytes ensures that the system only attacks infected 
tissues, and selection processes in the primary lymphoid organs eliminate self-reactive 
lymphocytes [22]. The neonatal period is especially important for these processes [23]. 
Selection might fail under certain conditions, which leads to uncontrolled immune responses 
against self-antigens. This occurs in autoimmune diseases, but there are a number of 
peripheral tolerance mechanisms that also limit the immune response to self-antigens. 
1.1.2.1 Humoral immunity  
The humoral immune response targets mainly extracellular microbes. B-lymphocytes release 
antibodies recognizing different protein, lipid, and carbohydrate antigens. B cells develop in 
the bone marrow, and their development in the bursa of Fabricius in birds has given them 
their name [24]. Conventional B cells, also called B2 cells, are derived from hematopoietic 
stem cells in bone marrow and fetal liver. A key regulator of B-cell development in the bone 
marrow is IL-7 [25]. This cytokine differentiates the hematopoietic stem cells into lymphoid 
progenitors, and it also has a key role later in the maturation process.  
Antibodies contain two antigen-binding fragments, which are formed by an immunoglobulin 
heavy chain and an immunoglobulin light chain. The heavy chains also form a crystallizable 
fragment (Fc) that binds various cellular receptors or complement proteins, which ensure that 
the antibody elicits an appropriate immune response when bound to antigen. Somatic 
recombination of the antigen receptor genes first occurs in the immunoglobulin heavy chain 
locus [26]. Recombination by the RAG-1 and RAG-2 proteins induces a unique receptor 
through the assembly of a variable (V), diversity (D), and joining (J) gene segment, with 
addition of untemplated nucleotides in the junctions. After the V(D)J recombination, the 
immunoglobulin heavy chain is expressed to form a pre-BCR. Cells with a functional pre-
BCR pass this positive selection process and move on to recombination of the 
immunoglobulin light chain locus.  
Before the B cells exit the bone marrow, a negative selection process occurs to identify self-
reactive cells [27]. Cells that pass the negative selection process can exit to the blood and 
circulate in secondary lymphoid organs as IgM+ immature B cells. Cells that fail the negative 
selection will undergo receptor editing of the immunoglobulin light chain. B cells presenting 
an altered BCR that remains autoreactive are eliminated. 
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Activation of B cells in secondary lymphoid organs depends on three signals: (i) recognition 
of the antigen by the BCR; (ii) interaction with T cells through MHC-TCR; and (iii) 
costimulatory receptors such as CD40L and cytokine stimulation such as IL-6, IL-21, B-cell 
activating factor, and a proliferation-inducing ligand. Activated B cells form germinal centers 
in order to develop high affinity BCRs through somatic hypermutation. This typically occurs 
in the white pulp in the spleen, where B cells interact with the antigen and Tfh cells. IL-4 and 
IL-21 from the Tfh cell provide survival signals to B cells presenting the highest affinity for 
the antigen. High-affinity B cells, with the best antigen-presenting capability, undergo clonal 
expansion, while lower-affinity B cells die. Germinal center B cells can be identified through 
the expression of CD95 and the GL7 ligand as well as by binding of peanut agglutinin. The 
antigen-binding fragment (Fab) of the BCR consists of three complementarity-determining 
regions (CDR). These regions have the highest frequency of mutations during somatic 
hypermutation. Activation-induced cytidine deaminase induces enzymatic mutations in these 
hypervariable regions, and an error-prone DNA polymerase repairs the segment causing 
modifications of the receptor [28]. 
The constant region of the immunoglobulin heavy chain defines the class of the antibody. 
Class switch recombination between different switch regions in the immunoglobulin heavy 
chain gene locus is determined by the cytokine milieu and changes the antibody isotype to 
IgA, IgE, or IgG. TGF- induces a switch to IgA that is secreted at mucosal sites. IL-4 
induces a switch to IgE that binds receptors on mast cells and is important in combating 
parasites. There are several IgG subtypes. IFN- gives an IgG3 switch in humans and an 
IgG2a switch in mice. IL-4 gives IgG1 and IgG4 in humans and IgG1 in mice. The isotype 
dictates the effector functions of the antibody [29]. The Fc-part of the IgG has different 
affinities for Fc-receptors and different abilities to activate the complement system. 
Differentiation of B cells can finally lead to plasma cells that secrete large amounts of 
antibodies [30]. Plasma cells express CD138, and long-lived plasma cells reside in the bone 
marrow. A small percentage of activated B cells differentiate into memory B cells, which are 
ready to be activated upon a new infection by the previously encountered pathogen. 
1.1.2.2 Cellular immunity 
T cells develop in primary lymphoid organs. Common lymphocyte progenitors in the bone 
marrow mature and are recruited to the thymus where they develop into naïve T cells [31]. 
The TCR resembles immunoglobulin [32] and uses RAG-dependent recombination to induce 
diversification and specificity to the receptor. An -chain and a -chain form the -TCR-
heterodimer. The TCR on  T cells similarly consists of a  and a -chain. Each - and -
chain consists of a constant region and a variable region with three CDRs. CDR3 is the most 
important region for antigen recognition. The -chain has an additional hypervariable area 
(HV4), but it does not take part in regular antigen recognition and is not considered a CDR. 
The TCR--chain is ontogenetically similar to the immunoglobulin heavy chain in the BCR, 
but lacks the Fc-part, and the TCR--chain is similar to the immunoglobulin light chain. The 
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generation of the TCR starts with V(D)J recombination of the -chain locus. The generated 
-chain is paired with a pre -chain and if this pre-TCR is functional, the recombination 
continues with the -chain locus. The successful formation of a -chain also shuts down 
recombination of the second -chain locus, a mechanism called allelic exclusion. When the 
-TCR is successfully formed, the cell starts to express both CD4 and CD8 molecules, and 
enters the double positive phase of maturation in the thymus.  
Cortical thymic epithelial cells (cTEC) express MHC class I and II. These molecules 
associate with self-peptides and interact with the T-cell precursors [33]. In a positive selection 
process, more than 90% of the immature thymocytes undergo apoptosis due to lack of affinity 
to MHC. The remaining cells with TCRs, with the ability to bind MHC, survive, and the 
continued expression of CD4 or CD8 is decided in this process. Depending on their TCR 
interaction with MHC class I or II, the cells develop into CD8-single positive or CD4-single 
positive T cells, respectively. These molecules are important co-receptors of the TCR-
complex and take part in intracellular phosphorylation during T-cell activation [34]. 
Medullary thymic epithelial cells (mTEC) control the negative selection crucial for T-cell 
tolerance induction. These cells express the autoimmune regulator (AIRE) transcription 
factor, which enables expression of tissue-restricted antigens (TRA) [35]. Peptides from these 
TRAs are loaded on MHC, while exogenous loading pathways are hampered. This allows a 
screen and elimination of T cells that recognize self-peptides. Each TRA is only expressed by 
a minor subset of mTECs. The single positive thymocytes perform a thorough scan of several 
mTECs over a 5-day period in the medulla. Dendritic cells and cTECs also participate in the 
negative selection process. The TCR signaling strength decides the fate of the cells [36]. The 
majority of high affinity single positive cells undergo apoptosis. Natural Tregs develop from 
cells with intermediate TCR signaling strength that upregulates Foxp3. Tregs maintain 
homeostasis and prevent immune reactions to self-antigens. Autoimmunity may occur when 
this central tolerance mechanism fails. The cells with low TCR signaling do not recognize 
self-peptides and mature into conventional naïve T cells.  
The TCR heterodimer has only a short intracellular part and needs to form a complex with 
CD3, which transmits the TCR activation signal intracellularly. The signal transduction starts 
a cascade of kinases and phosphatases leading to phosphorylation of Zap70, which attracts 
phospholipase C-. Next, transcription factors are activated. Nuclear factor of activated T-
cells (NFAT) is released in the nucleus and starts transcription of a broad range of genes such 
as IL-2. IL-2 is needed for long-term T-cell activation and proliferation [37]. 
The priming of naïve T cells occurs in secondary lymphoid organs and is MHC-dependent 
[38]. Several TCR-MHC complexes need to signal simultaneously to activate the T cell, 
while adhesion molecules stabilize the interaction between the T cell and APC. The TCR-
MHC interaction provides the first activation signal. The T cell also needs costimulation from 
ligands such as CD80 and CD86 expressed by the APC. These molecules ligate the 
costimulatory molecule CD28 on the T cell. This gives the second activation signal and 
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allows the T cell to initiate cell division and upregulate CD25, a high-affinity IL-2 receptor 
[39]. IL-2 is crucial for maintaining T-cell activation and drives clonal expansion. The T-cell 
production of IL-2 forms an autocrine loop [40]. This is the third signal that is needed for T-
cell activation, along with cytokines provided by the APC, crucial for the activation and 
differentiation into effector T-cell subsets (Fig. 1). 
CD8+ cytotoxic T cells screen nucleated cells for the presence of intracellular pathogens. 
Cytoplasmic proteins are digested in the proteasome and loaded on MHC class I, which is 
then transported to the cell surface. If the cell presents peptides on MHC class I that are 
identified as foreign, e.g., damaged self-peptides or derived from intracellular bacteria and 
viruses, the cell is killed. Damaged self-peptides are more common in tumor cells, and CD8+ 
T cells prevent tumor development. Normal self-peptides are tolerated through the thymic 
education process and are not recognized by the CD8+ T cells in the periphery. MHC 
molecules in man are called human leukocyte antigens (HLA). Three separate loci encode 
MHC class I: HLA-A, HLA-B, and HLA-C. The homologues in mice are H2-D, H2-K, and 
H2-L. MHC class I consists of an -chain linked to the non-polymorphic protein, -
microglobulin. The -chain contains a peptide-binding groove that fits an 8-11 amino acid 
long peptide. The groove needs to be occupied to stabilize the complex. Another domain of 
the -chain recognizes the CD8 co-receptor of the TCR complex and restricts MHC class I 
activation to CD8+ T cells. CD1d is another antigen presenting molecule that resembles 
MHC class I, but presents glycolipids to natural killer T cells. 
Dendritic cells, B cells, and macrophages are primarily responsible for presentation of 
extracellular antigens. These cells internalize microbes and foreign material by endocytosis. 
Internalized proteins are degraded in lysosomes and peptides generated in this process 
associate with MHC class II. The peptide-MHC complex is then transported to the cell 
surface where T cells can recognize the potential antigen. Humans have three MHC class II 
loci: HLA-DP, HLA-DQ, and HLA-DR. These loci contain polymorphic genes that ensure 
efficient antigen presentation of a broad range of peptides. The mouse homologues are H2-M, 
H2-A, and H2-E with the latter usually called IA and IE since they were initially named 
immune response genes. The MHC class II molecule consists of an -chain and a -chain, 
where a peptide groove is formed between the chains. The fitted peptides are usually 15 
amino acids long, but there is no steric hindrance for longer peptides. Similar to MHC class I, 
only complexes with a bound peptide are stable on the cell surface. The -chain contains a 
domain binding CD4, which restricts MHC class II presentation to CD4+ T-helper cells.  
1.1.3 T-cell subsets 
Naïve T cells express high levels of the surface molecule CD62L, a homing receptor for the T 
cells to enter secondary lymphoid tissues. CD62L binds glycosylation-dependent cell 
adhesion molecule-1 expressed in high endothelial venules. When a T cell finds its antigen, it 
differentiates into an effector T cell, proliferates, and secretes cytokines. CD4+ T cells 
differentiate into T-helper cells, and cytotoxic T cells are differentiated from CD8+ T cells. 
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The activated T cell downregulates CD62L and upregulates the cell adhesion molecule 
CD44, a marker for effector/memory T cells. Central memory T cells express both CD62L 
and CD44, together with CCR7, and are retained in the secondary lymphoid organs [41]. T 
effector/memory cells that lack CCR7 expression migrate to tissues. Integrins on their cell 
surface recruit them to inflammatory sites where the endothelium expresses adhesion 
molecules, such as vascular cell adhesion molecule-1 (VCAM-1). The threshold for 
reactivation of effector T cells in the periphery is lower than for naïve T cells. 
 
Figure 1. T-helper cell differentiation. Antigen is presented by a dendritic cell to a naïve CD4+ T-helper cell, 
which gets activated and differentiates into different subsets depending on the local cytokine milieu. Th1 cells 
are important for immunity to viruses, intracellular bacteria, and parasites. Th2 cells are important for immunity 
to extracellular parasites, including helminths. Th17 cells are important for immunity to extracellular bacterial 
and fungal infections. Tregs are involved in regulation of immunity and tolerance mechanisms. Tfh cells help B 
cells. 
1.1.3.1 Cytotoxic T cells 
CD8+ cytotoxic T cells are important in fighting viruses, intracellular bacteria, and tumor 
cells. They release perforin, granzymes, and granulysin when they identify an infected cell. 
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These cytotoxins enter the targeted cell, which lead to apoptosis through serine protease 
activity. Cytotoxic T cells can also induce cell death through FAS ligand expression that 
binds CD95 (also known as FAS receptor) on the target cell.  
1.1.3.2 T-helper 1 cells 
CD4+ T-helper cells can differentiate into different subsets depending of factors in the local 
milieu. The properties of Th1 and Th2 cells were the first to be described [42]. Th1 cells fight 
intracellular bacteria, viruses, and protozoa. Differentiation is driven by IL-12 and IFN- and 
leads to expression of the transcription factor T-bet encoded by the TBX21 gene. T-bet is a 
Th1 specific transcription factor that controls the hallmark cytokine of Th1 cells, IFN- [43]. 
IFN- can inhibit viral replication directly, but can also cause delayed type hypersensitivity 
and is associated with several autoimmune disorders [44, 45]. It upregulates MHC class II on 
APCs and activates pro-inflammatory responses of macrophages. Th1 cells can also provide 
help to B cells through CD40L expression and promote IgG isotypes efficient in 
opsonization. 
1.1.3.3 T-helper 2 cells 
Th2 cells are specialized in fighting extracellular parasites and cause eosinophilic 
inflammation. The influence of IL-4 on activated T cells leads to expression of the 
transcription factor GATA3, which induces differentiation to the Th2 lineage, while 
suppressing Th1 pathways [46]. This leads to production of IL-4, IL-5, and IL-13. IL-33 can 
also induce expression of these Th2-related cytokines [47]. Th2 cells are important for the 
humoral immune system and promote class-switching and production of neutralizing 
antibodies. Th2 cells are responsible for allergic inflammation, such as asthma, through the 
effects of IL-4 on B cells that promote IgE antibody production [48]. 
1.1.3.4 Th17 cells 
A third important subset of T-helper cells was named Th17 cells for their ability to produce 
IL-17 isoforms [49, 50]. IL-6 together with TGF- induces Th17 cell differentiation [51]. IL-
23 has an important role in the expansion and survival of Th17 cells. IL-1 and TNF can 
further amplify Th17 differentiation. A specific isoform of retinoic acid-related orphan 
receptor gamma in T cells (RORt) orchestrates Th17 cell differentiation [52]. Activated 
Th17 cells are specialized in fighting extracellular bacteria and parasites. Their signature 
cytokine is IL-17A, but also IL-17F, IL-21, and IL-22 are produced. IL-17A has pro-
inflammatory actions. It induces local CCL20 expression, a chemoattractant that recruits 
more Th17 cells to the site due to their expression of the CCL20-chemokine receptor CCR6 
[53]. Several studies have implicated involvement of Th17 cells in autoimmune diseases like 
multiple sclerosis, psoriasis, and rheumatoid arthritis [54-56]. Recently, IL-17A has been 
reported to have fibrogenic properties with an important role in wound-healing and liver 
fibrosis [57, 58]. 
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1.1.3.5 Regulatory T cells and peripheral tolerance mechanisms 
Tregs are important in immune homeostasis. Investigations initially described a suppressor 
activity that could restrain activation and proliferation of T cells [59]. The mechanism was 
difficult to pinpoint until CD25 was identified as a cell-surface marker of cells carrying this 
activity [60]. The cells could then be purified and studied in detail. Forkhead box P3 (Foxp3) 
is the key regulatory transcription factor of Tregs [61]. Mutations in the FOXP3 gene leads to 
the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) in 
humans [62] and mice with a mutation in the Foxp3 gene also suffer from fatal autoimmunity 
[63]. Natural Tregs develop in the thymus and circulate in the body to prevent reactivity of 
the immune system to self-antigens. Tregs can also be induced in the periphery by activation 
in the presence of TGF- and IL-2. Tregs secrete the anti-inflammatory cytokines: TGF- 
and IL-10, with TGF- influencing neighboring T cells to become induced Tregs [64]. 
Suppressive mechanisms include IL-2 deprivation that leads to apoptosis of the effector T 
cells [65]. Tregs also have various cell-mediated suppressive mechanisms and can decrease 
costimulation and antigen presentation by APCs [66]. Type 1 regulatory T (Tr1) cells are 
Treg-like cells, but lack Foxp3 expression. They mainly reside in the gut and have the ability 
to produce large amounts of IL-10, which makes them important in mucosal tolerance. IL-10 
inhibits presentation of antigens, decreases expression of costimulatory molecules, and blocks 
cytokine and chemokine secretion [67]. 
T-cell activation in the absence of pro-inflammatory mediators may lead to induced tolerance 
in the periphery. APCs that are not activated by, e.g., TLR ligation, express low levels of 
costimulatory molecules. The recognition of its antigen without costimulation promotes T-
cell anergy. Anergic T cells are unable to mount a normal immune response against their 
antigens even though presentation may occur with costimulation later. Tolerogenic dendritic 
cells are specialized in presenting self-peptides to induce antigen-specific Tregs. Their 
functionality is suggested to be mediated through cytokine secretion, such as IL-10 and TGF-
, and lack of costimulation [68]. In addition, indoleamine 2,3-dioxygenase (IDO) activity in 
tolerogenic dendritic cells leads to production of tryptophan metabolites that inhibit activated 
T cells. 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is expressed on activated T cells to 
reduce the immune response and to restore homeostasis after clonal expansion. It binds to 
CD80 and CD86 on APCs and prevents their binding of the costimulatory molecule CD28 
[69]. Tregs constitutively express CTLA-4, and it is critical for their ability to suppress 
immune responses [70]. Programmed cell death protein 1 (PD-1) is also an important 
inhibitory surface receptor on T cells. It binds PD-L1 and PD-L2 and prevents excessive T-
cell activation and autoimmunity [71]. All these mechanisms act together to regulate the 
immune response, but immune tolerance is not indefectible. There are several examples of 
autoreactive T cells that escape control and cause autoimmune disorders. 
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1.1.3.6 T follicular helper cells 
Tfh cells are a distinct subset of antigen-experienced T-helper cells that are specialized to 
assist follicular B cells in their formation of germinal centers [72]. Tfh cells depend on IL-6 
and IL-21 to activate their lineage-specific transcriptional profile with Bcl-6 as the 
transcriptional master regulator [73]. Tfh cells secrete IL-21, which provides proliferative 
signals to activated B cells and also forms an autocrine loop during the Tfh cell 
differentiation. After antigen recognition, the Tfh cell upregulates CXCR5 to home to 
germinal centers. Through expression of CD40L, the cells trigger and maintain germinal 
center reactions. The ligation of CD40 on B cells by CD40L activates activation-induced 
cytidine deaminase that drives somatic hypermutation and causes antibody class-switching.  
1.2 ATHEROSCLEROSIS 
Cardiovascular disease is the main cause of death in the world, with ischemic heart disease 
and stroke accounting for one in every four deaths worldwide [74]. Atherosclerosis is the 
underlying cause in most cases. The disease progresses slowly with chronic inflammation and 
a build-up of lipid-laden plaques in large- and medium-sized arteries. Atherosclerosis 
typically remains unnoticed over several decades until a rupture of the plaque elicits 
thrombus formation that occludes the vessel and leads to ischemic tissue damage. 
1.2.1 The pathogenesis of atherosclerosis 
A normal artery consists of an intima layer with endothelial cells and sparsely distributed 
smooth muscle cells, a media layer with smooth muscle cells and elastic lamellae, and a 
surrounding adventitial layer with loose connective tissue [75]. An intimal accumulation of 
LDL offsets atherosclerosis development. Already in young adults, coronary atherosclerosis 
is evident as fatty streaks [76, 77]. The proteoglycan-binding and retention of LDL in the 
subendothelial space is the initiating event [78]. The trapped lipoproteins are biochemically 
modified by proteases and lipases, leading to aggregation and increased proteoglycan binding 
[79]. Oxidative modifications by myeloperoxidase, lipoxygenase, and reactive oxygen 
species lead to formation of oxidized LDL (oxLDL) that could elicit an innate inflammatory 
response [80]. 
In response to the trapped and modified lipoproteins and at sites in the arterial tree with 
turbulent blood flow, endothelial cells start to express adhesion molecules, such as VCAM-1 
[81, 82]. Circulating monocytes and other leukocytes are recruited to these sites. The 
infiltrating monocytes differentiate into macrophages in response to M-CSF and GM-CSF 
produced by endothelial cells [83]. The monocyte-derived macrophages are a major cell 
population in atherosclerotic plaques and can proliferate locally [84, 85]. They express 
scavenger receptors, of which scavenger receptor class-A and CD36 have been identified to 
be the most important for uptake of modified LDL [86]. Scavenger receptors are not 
downregulated in response to intracellular cholesterol accumulation. The continued 
engulfment of lipids leads to macrophage foam cell formation [87]. The large and foamy cells 
are trapped within the arterial intima and have compromised migratory capacity [88]. 
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1.2.1.1 Risk factors 
The Framingham heart study started in 1948 with the aim to identify preventable risk factors 
for cardiovascular disease. After 6 years follow-up, elevated blood pressure, 
hypercholesterolemia and left ventricular hypertrophy were identified as independent 
predictors of risk for developing coronary heart disease [89]. Later, cigarette smoking, lack of 
exercise, obesity, diabetes, and low HDL levels were identified as risk factors.  
Inflammation was associated with myocardial ischemia through measurements of the acute 
phase reactant, C-reactive protein (CRP), in plasma [90]. Later it was recognized that 
elevated CRP levels, as an independent risk factor, could predict future cardiovascular events 
[91, 92]. Clinical symptoms of atherosclerosis typically do not arise until later in midlife 
illustrating how age is an important risk factor [93]. Lesion development is influenced by 
environmental factors, such as diet, but atherosclerosis is not a modern disease. It has existed 
in several ancient cultures with disparate eating habits [94]. Previously, males have been 
assumed to be at greater risk to develop cardiovascular disease. This is contradicted by 
current mortality statistics that show a small predominance of female deaths by 
cardiovascular disease [95]. Genetic factors are important for atherosclerosis and genome-
wide association studies have identified several single nucleotide polymorphisms linked to 
increased risk for coronary artery disease [96]. The most robust genetic association is located 
in the chromosome 9p21 locus and has been implicated in trans-regulation of interferon 
signaling [97]. Some of the other identified loci are also linked to inflammation, but the 
associations are weak in comparison to other inflammatory diseases. This probably reflects a 
complex and multifactorial origin of the genetic contribution to atherosclerosis. 
1.2.1.2 Symptoms of atherosclerosis 
As the atherosclerotic plaque grows, it becomes more and more complex. Fatty streaks 
develop into fibro-fatty lesions that become advanced plaques. Plaques might even grow into 
a large stenosis that narrows the lumen. This could impair blood flow with symptoms such as 
angina pectoris or intermittent claudication. Plaque rupture or endothelial erosion may also 
occur. This leads to exposure of thrombogenic material, such as tissue factor, collagen, and 
phospholipids. Platelets rapidly aggregate, with ensuing coagulation, and thrombus 
formation. This blocks the blood flow and causes ischemia and tissue damage. Thrombus 
formation in a coronary artery may lead to myocardial infarction, and a peripheral thrombus 
may lead to gangrene. If a rupture occurs in a plaque located in a carotid artery, a stroke may 
be the consequence due to cerebral embolism. 
1.2.1.3 Plaque stability 
Plaque ruptures are estimated to account for around 70% of coronary thrombosis events [98]. 
The remaining 30% emphasize the importance of other mechanisms for clinical disease. 
Endothelial erosions are defined as the absence of endothelial lining leading to an acute 
thrombus formation without signs of cap rupture [99]. The underlying intima is usually rich 
in smooth muscle cells and proteoglycan matrix. Importantly, observations indicate that 
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endothelial erosions are becoming more frequent and modern pharmaceutical treatments with 
statins might drive this change [100, 101]. New successful therapies probably need to prevent 
both rupture and erosion or be given to substratified risk groups for either of these conditions. 
Large and complex plaques contain a core with dying cells, both apoptotic and necrotic, 
cholesterol crystals, and other extracellular material. The necrotic core is covered by a fibrous 
cap, and at the shoulder regions of the plaque, accumulation of immune cells, such as T cells, 
are seen [102]. Symptoms of atherosclerosis typically arise when the cap fails to withstand 
the pulsatile force from the blood pressure and superficial fissures are formed, usually near 
the edges of the plaque [103]. Plaques vulnerable to rupture are characterized by a thin 
fibrous cap, a large lipid-filled necrotic core, and on-going inflammation [104, 105].  
Smooth muscle cells and collagen have a central role in plaque stability. TGF- stimulates 
extracellular collagen maturation and positively regulates collagen synthesis by smooth 
muscle cells [106, 107]. Mature collagen provides mechanical strength to the fibrous cap. 
IFN- is a powerful destabilizing agent and inhibits smooth muscle cell differentiation and 
proliferation as well as collagen production and maturation [106, 108, 109]. Matrix 
metalloproteinases degrade collagen fibers and promote plaque vulnerability [110]. As an 
illustration, mast cells that are commonly found at sites of plaque rupture, release proteases 
that degrade matrix and activate matrix metalloproteinases [111]. Atherosclerotic 
calcification usually provides stability to the plaques, but when the calcification occurs in 
small nodules, it adds instability. The latter is seen as spotty calcifications with 
ultrasonography and is associated with cardiovascular events [112]. Plaque stability can be 
estimated with imaging methods, such as ultrasonography, but there is a need for better 
techniques with higher resolution.  
1.2.2 The immune response in atherosclerosis 
Atherosclerosis is a chronic inflammatory disorder, although the contribution of cholesterol 
to the disease has been the main topic in the public debate [113]. The link between 
cholesterol and atherosclerosis became evident in 1913 when Nikolay Anichkov fed 
cholesterol to rabbits and investigated their aortas [114]. In 1856, Rudolf Virchow laid forth a 
hypothesis about how inflammation may initiate plaque formations in the arterial wall [115]. 
In support of this, recent knowledge has connected atherosclerotic cardiovascular disease 
with other inflammatory diseases. Patients with rheumatoid arthritis, psoriasis, or systemic 
lupus erythematosus all have increased risk for myocardial infarction [116, 117]. Low-grade 
inflammation, such as periodontitis, also gives an increased risk [118].  
Associations between infections and atherosclerosis have led to a hypothesis about an 
infectious cause of atherosclerosis. Chlamydia pneumoniae could accelerate experimental 
atherosclerosis [119], but the effect depends on several factors [120] and antibiotics do not 
benefit coronary artery disease patients [121]. In addition, germ-free mice can develop 
atherosclerosis [122], but this study is far from conclusive. Taken together, there is no causal 
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link between an infectious agent and atherosclerosis. Instead, evidence points to 
atherosclerosis being an autoimmune disorder.  
After the discovery of immune cells in atherosclerotic plaques using monoclonal antibodies 
[102], a great focus has been put on inflammation in cardiovascular research. This has led to 
major findings regarding the pathogenesis of atherosclerosis as well as new therapies such as 
drug-coated stents used for percutaneous coronary interventions. These metal stents are 
coated with an immuno-suppressive drug, such as rapamycin, which also inhibits 
proliferation of smooth muscle cells and decreases the restenosis frequency [123, 124]. Low 
dose aspirin is used clinically for platelet inhibition and not as an anti-inflammatory drug. For 
other anti-inflammatory drugs, e.g., cortisone and non-steroid anti-inflammatory drugs, 
adverse effects make them unsuitable for long-term treatment of cardiovascular 
inflammation. There is a need for more specific treatments. Several new anti-inflammatory 
treatments are under development [125], and hopefully a range of drugs will become 
available in the future. 
1.2.2.1 Innate immune activation in atherosclerosis 
In vitro studies have shown that oxLDL promotes innate immune activation in macrophages. 
In atherosclerotic lesions, macrophages have nuclear factor -light-chain-enhancer of 
activated B cells (NF-B) translocated to their nuclei as a sign of innate immune activation 
[126]. Macrophages in the plaques express various TLRs. Modified LDL and products 
thereof might be endogenous ligands to TLR2 and TLR4 [127, 128]. Other ligands, both 
endogenous and exogenous for TLRs expressed by macrophages have been suggested as well 
[129]. The downstream signaling molecule of several TLRs, Myd88, confers an important 
pro-atherosclerotic signal, but also transmits IL1- and IL-18 signals [130]. 
Lysophosphatidylcholine and oxidized non-esterified fatty acids generated during LDL 
oxidation by lipoprotein-associated phospholipase A2 could also activate the innate immune 
system [131]. All these events are likely to be important factors that initiate and contribute to 
the maintenance of the inflammation in the forming lesions. Nonetheless, preventive 
measurements against innate immune activation with anti-oxidants or selective lipoprotein-
associated phospholipase A2 inhibition have failed to show benefit in patients [132-134]. 
Cholesterol crystals form in foam cells and can activate the NLRP3 inflammasome, leading 
to IL-1 release [135, 136]. The NLRP3 inflammasome contains leucine-rich repeats that 
sense intracellular danger signals. The activated inflammasome recruits caspase-1 that 
cleaves the pro-form of IL-1 to its functional and releasable form. This provides a clear link 
between cholesterol metabolism and innate immune activation. Inhibition of IL-1 to prevent 
cardiovascular events, is currently under evaluation in clinical trials [137]. The released IL-1 
acts on smooth muscle cells to produce IL-6 [138], which in turn signals to the liver to 
produce CRP [75]. 
Innate immune cells, such as neutrophils, mast cells, natural killer cells, and natural killer T 
cells have been suggested to play important roles during atherogenesis, but are minor 
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populations in the plaques in comparison to macrophages and CD4+ T cells. In 
hypercholesterolemic mice, neutrophils are recruited during the initiation of atherosclerosis, 
but they are not present at later stages [139]. Mast cells may play a role in plaque stability 
with their matrix degrading enzymes [111]. Natural killer cells and natural killer T cells 
aggravate atherosclerosis, possibly due to IFN- release [140, 141]. Natural killer T cells that 
produce IL-10, may on the other hand, limit disease development [142].  T cells do not 
seem to impact atherosclerosis [143, 144]. Taken together, several small populations of innate 
immune cells play significant roles at different stages of disease development, but the main 
innate immune effector cell type in the plaques is macrophages. 
1.2.2.2 Adaptive immune activation in atherosclerosis 
HLA-DR is expressed by several cell types in the atherosclerotic plaque and presents antigen 
to CD4+ T cells [145]. Genome-wide association studies have implicated associations 
between MHC and coronary artery disease [146]. The regulation of MHC expression has also 
been associated with myocardial infarctions [147], and certain HLA haplotypes are associated 
with either increasing risk or conferring protection, although the associations are weak [148]. 
MHC class II expressing cells, together with the significant number of T cells present in the 
atherosclerotic plaques at all stages of the disease, form the basis of the adaptive immune 
response in atherosclerosis [80]. 
Dendritic cells are found in atherosclerotic plaques and in the adjacent adventitia [149]. They 
take up plaque-derived antigens and migrate to lymph nodes where they display these 
antigens to a large number of naïve T lymphocytes [150]. Autoantigens derived from the 
LDL particle have been shown to be important for atherosclerosis. The frequent presence of 
anti-oxLDL antibodies shows that B cells react to oxLDL [151]. In general, these antibodies 
are more prevalent in coronary artery disease patients than healthy controls [152]. As oxLDL 
is a complex particle with disparate properties and large heterogeneity, it harbors many 
potential epitopes of which lysophosphatidylcholine, phosphorylcholine, and different 
peptides from Apolipoprotein (Apo) B100 have been identified [153-155]. Anti-oxLDL 
antibodies can be either IgM or IgG, implicating that an isotype class-switch takes place, 
which, in turn, indicates T-cell help. Indeed, T cells from humans with atherosclerosis 
recognize LDL components presented by APCs [156]. 
Heat shock protein (hsp) 60/65-reactive T cells have also been isolated from atherosclerotic 
plaques [157, 158]. Autoantibodies against hsp60/65 have been reported to be pathogenic, 
mediating cytotoxicity to endothelial cells, and evoking fatty streak formation [159, 160]. 
Heat-shock proteins are highly conserved, from bacteria to man, and produced in response to 
stressful conditions, such as hemodynamic strain and inflammation. Substantial antibody 
cross-reactivity exists between human hsp60 and the hsp60/65 counterparts in Chlamydia and 
Mycobacteria, which possibly explains these microbes’ association with atherosclerosis. 
Induced mucosal tolerization to hsp65 protects against experimental atherosclerosis [161], but 
regular immunization against hsp65 could also induce such effect [162]. Further studies are 
needed to disentangle the role that heat shock proteins play as autoantigens. Other 
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immunogens that have been implicated in atherosclerosis are Apo-H (previously known as 
2-glycoprotein I) [163] and aldehyde-modified extracellular matrix proteins [164]. 
Vaccination against modified LDL confers a clear protective effect in experimental 
atherosclerosis models [165-168]. Proposed protective mechanisms include both cellular and 
humoral immunity as well as natural IgM antibodies [169]. Studies have focused on 
oxidation- or malondialdehyde-modified epitopes in LDL, but one of the initial findings was 
a superior protection by immunization with native LDL [166]. Protection from 
atherosclerosis can also be achieved through vaccination with native peptides from the ApoB-
protein in LDL [170, 171]. Some protocols designed to induce mucosal tolerance implicate 
ApoB-specific Tregs with TGF- and IL-10 secretion to confer the protection [172-174]. 
Dendritic cell vaccination that promotes development of ApoB-specific Tregs confirms this 
notion [175]. In humans, anti-oxLDL IgG levels in plasma are associated with coronary 
artery disease, while IgM levels show the inverse relationship [176].  
The protective effect of antibodies could be: (i) neutralization of the pro-inflammatory 
properties of oxLDL, (ii) inhibited scavenger receptor uptake of oxLDL by foam cells, or (iii) 
Fc-mediated clearance of the particles [177]. Clearance of circulating particles would lower 
plasma cholesterol levels. An inverse association between serum cholesterol and oxLDL 
antibody titers in humans supports this notion [178]. This association has also been reported 
in LDL-vaccinated animals [168], and several other immunization studies show a decrease in 
total plasma cholesterol [179-181]. In addition, atheroprotection and LDL reduction are also 
seen in passive immunizations of hypercholesterolemic mice [182]. These studies have 
proposed that the protective mechanism to be neutralization of oxLDL [168, 182], inhibition 
of scavenger receptor uptake by foam cells [179, 181], or modulation of cellular immune 
responses [179, 180]. Reduction of LDL cholesterol mediated by anti-LDL antibodies seems 
to be a protective mechanism that has been overlooked or downplayed. Most studies have 
focused on modified LDL immunizations and disregard the clear protection from vaccination 
with native LDL [166, 180]. Together with the frequently seen autoantibodies against native 
ApoB peptides in humans [155], this suggests that adaptive immune responses to native LDL 
have a central role in atherosclerosis. 
Interestingly, the atherosclerosis-associated immune response is not restricted to the intimal 
plaques and draining lymph nodes. Microvessels, lymphatics, and small conduits are formed 
that open a communication between the plaque and the adventitia [183, 184]. The media layer 
is normally immune-privileged, possibly through IDO expression [185], but tertiary lymphoid 
organs are formed in the adventitia located underneath the advanced plaques [183, 186, 187]. 
This is an interaction site for dendritic cells, B cells, and T cells. In these tertiary lymphoid 
structures, B cells are activated by antigens derived from atherosclerotic plaques and form 
germinal centers. More studies are needed to elucidate the specificity of the adaptive immune 
cells in these locations since aortic tertiary lymphoid organs seem to be of substantial 
importance for atherosclerosis development [188, 189]. 
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1.2.2.3 B cells in atherosclerosis 
B cells are only occasionally detected in the atherosclerotic plaques [102, 190]. A protective 
immunity mounted by B cells in spleen has been established through splenectomy and B cell 
transfer experiments in atherosclerotic mice [191], and this immunity is supported by effects 
seen in mice lacking B cells [192]. In addition, an increased risk to die from myocardial 
infarction is evident in splenectomized patients [193]. In contrast, B-cell depletion using anti-
CD20 antibodies was reported to protect against experimental atherosclerosis [194, 195]. 
Indications of a beneficial effect on endothelial dysfunction exist in humans treated with anti-
CD20 antibodies [196]. However, it should be considered that treatment with anti-CD20 only 
targets conventional B2 cells, and the mechanistic understanding of how these cells promote 
the disease remains largely elusive. B1 cells and antibody-producing plasma cells are 
unaffected by anti-CD20 treatment and could thus confer a protective effect. B1 cell transfer 
protects against atherosclerosis with production of germ-line encoded natural antibodies 
[197]. Especially the T15-idiotype, which is important to fight Streptococcus pneumoniae, 
has been suggested to have a beneficial effect during atherogenesis [154]. The proposed 
mechanism is molecular mimicry between the microbe and oxLDL. Indeed, pneumococcal 
vaccination protects against experimental atherosclerosis by blocking oxLDL uptake and 
lowering plasma cholesterol [181]. However, mice with a specific abrogation of T15-idiotype 
natural antibodies do not have increased atherogenesis [198]. Several different IgM 
antibodies with oxLDL reactivity probably have overlapping effects.  
Similar to S. pneumoniae, apoptotic cells are immunogenic and share oxidation-specific 
epitopes with oxLDL particles [199]. Humoral immunity against these oxidation-specific 
epitopes occurs naturally and protects against atherosclerosis. The protective effect can be 
strengthened through apoptotic cell immunization, which lowers plasma cholesterol [200]. 
Possibly, IgM against (ox)LDL provides protection through neutralizing pro-inflammatory 
epitopes and by inhibiting scavenger receptor-mediated uptake, while anti-LDL IgG lowers 
cholesterol through immune complex formation.  
1.2.3 T cells in atherosclerosis 
Activated T cells are a significant cell population in atherosclerotic plaques [201, 202]. These 
T cells are antigen-experienced memory cells bearing evidence of an oligoclonal expansion 
[203, 204]. Mice with severe combined immunodeficiency, lacking both T and B cells, have a 
reduced development of atherosclerosis [205], and transfer of LDL-specific CD4+ T cells to 
these mice severely aggravates the disease [206]. A specific lack of CD4+ T cells inhibits 
atherosclerosis development [207, 208], although the Cd4-/- mouse model is far from optimal 
and still contain MHC class II restricted T cells [209]. CD8+ T cells do not have a major 
impact on experimental atherosclerosis in hyperlipidemic mice [144, 208], and are a minor 
population in comparison with CD4+ T cells, especially in mouse models of atherosclerosis. 
Treating Apoe-/- mice with a ligand for the costimulatory molecule CD137 increases CD8+ T-
cell recruitment to the plaque and promotes atherosclerosis [210]. CD8+ Tregs may also 
influence atherosclerosis development [189]. Nonetheless, CD4+ T-helper cells are the main 
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adaptive effector cells in the atherosclerotic plaques. These T-helper cells react to peptide 
fragments from the ApoB100-protein in LDL when presented on MHC class II [156, 211].  
Opposite to the innate response, oxidation of LDL blunts T-cell activation and possibly 
destroys the epitope. In immunized mice, several clones with an MHC class II restricted 
reaction to native LDL were shown to carry a TCR with the -chain TRBV31 [211]. The 
mice were humanized in regard to their LDL particles, which made induction of an 
autoimmune response to human lipoproteins possible. Blocking the TRBV31+ T-helper cells 
by vaccinating against a TRBV31-derived peptide protects from atherosclerosis [211]. 
Clearly, LDL-reactive T cells exist both in humans [156] and mice [211], but are difficult to 
assess experimentally. Immunization protocols can expand these T cells, but their actions are 
then influenced by the adjuvant in the vaccine preparation. The different effects of CD4+ T-
helper cell subsets on atherosclerosis are discussed in detail below. 
1.2.3.1 Th1 cells in atherosclerosis 
Th1 cells secrete IFN- and this cytokine promotes monocyte infiltration, macrophage 
activation, and foam cell formation. IFN- also advances Th1-differentiation in synergy with 
IL-12. In human atherosclerotic plaques, a predominance of a Th1 immune response can be 
observed, and T cells isolated from human plaques respond in a Th1-fashion ex vivo [156, 
212]. The pro-atherosclerotic effect of Th1 cells has been shown in several animal 
experiments. IFN--deficient mice [213-215] and knockout mice of the Th1-trancription 
factor T-bet [216] have reduced atherosclerosis development. These studies also confirm the 
strong effect of IFN- on stimulating antigen-presentation with upregulation of MHC class II 
as well as the ability of IFN- to inhibit smooth muscle cell proliferation and expression of -
smooth muscle actin, effects that were initially described in [108, 145, 217, 218]. These 
effects make the plaque more vulnerable to rupture, the key event responsible for clinical 
manifestations of atherosclerosis, such as myocardial infarction and ischemic stroke. In 
conclusion, most evidence points to atherosclerosis being a Th1-driven disease, with a 
multitude of pro-atherosclerotic effects mediated by IFN-. However, several other cells in 
the plaque, such as macrophages and natural killer T cells, also have the ability to produce 
IFN-. The relative contribution of IFN- in the plaques from these cells compared to Th1 
cells is not clarified [140, 219, 220]. 
1.2.3.2 Th2 cells in atherosclerosis 
From the classical dichotomy of dividing T-helper cell subsets in Th1 and Th2, it is clear that 
Th1 cells are more frequent in atherosclerotic plaques, with Th2 cells much less common 
[212]. Severe hyperlipidemia could switch the balance toward a Th2 phenotype in Apoe-/- 
mice, but the impact of this on atherosclerosis is uncertain [221]. Compound-knockout mice 
have been used to assess the separate effects of Th2-related cytokines. Most studies of IL-4 
point toward a disease promoting effect [222, 223], while IL-5, IL-13, and IL-33 may limit 
the disease development [169, 224, 225]. The protective mechanism of IL-5 could be 
mediated through its stimulation of natural antibody production by B1 cells. A single 
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nucleotide polymorphism in the IL-5 locus is associated with human coronary heart disease, 
corroborating the experimental findings [226]. Nonetheless, Th2 cells are infrequent in 
human atherosclerotic plaques and have an undecided importance. 
1.2.3.3 Th17 cells in atherosclerosis 
The impact on atherosclerosis by Th17 cells has been difficult to assess clearly. Th17 cells 
are a minor population in the plaques [227], and IL-17A, the signature cytokine of Th17 cells, 
is also produced by other cells, e.g., mast cells and neutrophils [228]. Several experimental 
studies have described conflicting effects on atherosclerosis development. Publications 
investigating IL-17A deficient Apoe-/- mice have reported increased [229], decreased [230], 
or no effect at all on lesion size [231]. A proposed explanation was an upregulation of the 
family member gene IL-17F in the absence of IL-17A, but neutralization of IL-17F in the IL-
17A deficient animals did not impact atherosclerosis [231]. The different effects might be 
attributed to different effects of IL-17A at different stages of the disease development and 
other parameters.  
The use of anti-IL17A neutralizing antibodies and other methods of IL-17A blockade have 
shown more coherent results with a reduction in lesion size [232-234]. Conflicting results 
have been reported and are suggested to be due to different antibodies and treatment 
protocols [235, 236]. In accordance with the results of a proatherogenic role for IL-17A, 
knocking down the IL17-receptor leads to less atherosclerosis [237, 238], and administering 
recombinant IL-17A promotes the disease [232]. These various effects of IL-17A have been 
reported to be mediated through both pro- and anti-inflammatory cytokines, effects on 
chemokines, matrix metalloproteinases, and adhesion molecules. Interestingly, 
proatherogenic conditions and oxLDL might induce Th17 cell differentiation [239].  
Apart from the various reports on lesion size, investigations of plaque composition and other 
experimental evidence point toward a plaque-stabilizing role for IL-17A [229, 231]. In 
response to acute coronary syndrome, Th17 cell percentage and IL-17A cytokine production 
are elevated in the blood [240]. Patients without this response due to low IL-17A levels in 
sera have a higher risk for recurrent cardiovascular events [241]. This supports the notion of 
IL-17A’s involvement in plaque stability and prompts for a study that establishes this 
connection mechanistically. Such explorations were undertaken in paper I of this thesis. In 
summary, experimental evidence points toward a complex role of IL-17A in atherosclerosis 
with diverse effects on different cell types in a multifaceted interplay with other cytokines. 
1.2.3.4 Tregs in atherosclerosis 
Minor populations of Foxp3+ Tregs are found in atherosclerotic plaques at all stages of the 
disease [242]. In experimental atherosclerosis, Treg number in lesions may vary [243], but 
Tregs have an important role to decrease inflammation and disease progression. Depletion of 
Tregs with anti-CD25 antibodies increases atherosclerosis in Apoe-/- mice [244]. Dendritic 
cell vaccination that evokes a cytotoxic response specifically to Foxp3+ T cells repeats this 
finding [245]. Transfer of Tregs is protective [244, 246] and similarly, expanding the Treg 
  19 
population by using experimental protocols reduces atherosclerosis [247-249]. Treg 
expansion has been shown to induce regression of atherosclerosis [250] or create a plaque 
stabilization effect [251]. Antigen-specific Tregs may have an important protective role 
during atherogenesis as indicated by experimental vaccination studies [173, 174, 252]. 
Several studies have pointed out an important role for the anti-inflammatory cytokine IL-10 
during atherogenesis with its ability to prevent disease progression [253-255]. The other 
Treg-associated cytokine, TGF- has a more complex role being a potent regulatory cytokine 
with diverse effects. Posttranscriptional and posttranslational modifications regulate TGF- 
activity [256]. For immune cells, TGF- regulates differentiation, tolerance, and proliferation. 
Disrupting TGF- signaling in T cells leads to large, inflamed lesions in Apoe-/- mice [257]. 
However, the role of TGF- in atherosclerosis lesion development is not conclusive [258, 
259]. Various outcomes regarding atherosclerotic burden are evident when studying the 
general effect of TGF- without targeting a special cell type [260-264]. Nonetheless, all these 
studies agree on a plaque stabilizing effect of TGF- with stimulation of collagen production. 
Tregs and their effector molecules have been implicated in the regulation of cholesterol 
metabolism. Overexpression of IL-10 lowers VLDL and LDL [265] and Il10-/-xApoe-/- mice 
have elevated LDL levels [255]. In addition, Treg expansion in a regression model associates 
with reduced serum cholesterol [251]. Altogether, experimental evidence indicates that Tregs 
protect from atherosclerosis by dampening inflammation, with a possible involvement in the 
stabilization of plaques and regulation of serum cholesterol. 
1.2.3.5 Tfh cells in atherosclerosis 
In atherosclerosis, Tfh cells are not well-characterized. Tfh cells provide help to B cells, and 
both pro- and anti-atherosclerotic effects of B cells have been reported. Tertiary lymph 
structures in the proximity of the aorta contain germinal center B cells and effector T cells 
likely to be Tfh cells [183]. These lymphoid structures have been suggested to protect against 
atherosclerosis development [188]. Conversely, pro-atherosclerotic effects of Tfh cells have 
been suggested [189]. Further studies are needed to elucidate the mechanisms of action and 
effect of Tfh cells on atherosclerosis.  
No comprehensive report on the effects and role of IL-21 in atherosclerosis exist to this date. 
The exploration of Tfh-cell specificity, preferably isolated from tertiary lymphoid structures 
adjacent to the plaques, will be of great interest to understand Tfh function. Investigations 
into the specificity and effector functions of B cells are also crucial for the interpretation of 
the role that Tfh cells play in atherosclerosis. 
1.3 LIPID METABOLISM 
All living organisms continuously consume energy, mainly in the form of adenosine 
triphosphate (ATP), to maintain structure and run biological processes. ATP is synthesized 
during oxidation of carbohydrates, lipids, and proteins. Cholesterol is one of the most 
abundant lipids in cells of higher eukaryotes constituting of up to 25% of the cell membrane 
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[266]. Cholesterol has a rigid and hydrophobic structure contributing to membrane stiffness 
and cholesterol-rich microdomains within the cell membrane are important for 
transmembrane receptors and their signaling [267]. Metabolites of cholesterol, such as 
steroids and vitamin D, are important cell signaling molecules. Bile acids are also derived 
from cholesterol and important in forming micelles with dietary lipids to promote intestinal 
uptake. Of the cholesterol in the body, approximately 30% is derived from de novo synthesis 
and 70% is absorbed from the diet [268]. This relationship varies depending on genetic 
factors and diet.  
All nucleated cells can synthesize cholesterol from Acetyl-CoA through the mevalonate 
pathway. The rate-limiting step is the conversion of hydroxymethylglutaryl CoA (HMG-
CoA) to mevalonate by HMG-CoA reductase. The lipid-lowering statin drugs inhibit HMG-
CoA reductase and reduces incidence of cardiovascular events in primary prevention to high-
risk individuals [269] and in secondary prevention to coronary heart disease patients [270]. 
Statins typically decrease plasma cholesterol by around 30%. The lipid-lowering effect is not 
mainly caused by a reduction in biosynthesis of cholesterol, but a concomitant upregulation 
of LDL receptors in the liver [271, 272]. 
Cholesterol esterification with addition of a fatty acid residue makes the cholesterol molecule 
more hydrophobic. Cholesterol esters fit less well in the cell membrane and form intracellular 
lipid droplets. The cholesterol synthesis, uptake, and processing is controlled by sterol 
regulatory element binding proteins (SREBP) [273]. SREBPs are sterol-sensing transcription 
factors that are activated to increase cellular cholesterol levels through uptake and de novo 
synthesis of cholesterol.  
The main lipid content in food is triglycerides that consist of a glycerol molecule and three 
fatty acid residues. Fatty acids exist in a saturated form with the maximal amount of 
hydrogen bound to the carbon backbone and in unsaturated forms with carbon double bounds 
in the tail structure. Triglycerides cannot pass through cell membranes, and they need to be 
broken down by lipases into free fatty acids and glycerol. In adipocytes, they are assembled 
into triglycerides again, and this is the main form of energy stored in the body.  
1.3.1 Lipoproteins 
The lipid transfer system that handles and distributes cholesterol in the body is tightly 
regulated. Hepatocytes in the liver orchestrate lipid metabolism and distribute cholesterol-rich 
lipoprotein particles around the body. Lipoproteins consist of a shell with a structural protein 
non-covalently linked to phospholipids and unesterified cholesterol and a core with 
cholesteryl esters and triglycerides. The various lipoproteins are classified according to their 
density (Table 1). Normal plasma cholesterol levels in humans are <5.0 mmol/l, and usually 
levels >6.0 mmol/l are classified as hypercholesterolemia. Total triglyceride levels are 
recommended to be below 1.7 mmol/l. Guidelines for risk assessments take several risk 
factors in consideration to determine suitable intervention [274]. Dyslipidemia refers to the 
presence of elevated levels of one or several fractions of plasma lipids. 
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Table 1. The characteristics of the main lipoprotein classes [275]. 
Particle Main apolipoprotein Main component Size (nm) Density (g/ml) 
Chylomicron B48, C, E Triglycerides 100-1000 <0.95 
VLDL B100, C, E Triglycerides 30-80 0.95-1.006 
IDL B100, E Triglycerides and cholesterol 25-35 1.006-1.019 
LDL B100 Cholesterol 18-25 1.019-1.063 
HDL A1, A2 Protein 5-12 1.063-1.210 
1.3.1.1 Chylomicrons 
Dietary cholesterol and triglycerides are taken up in the gut and packaged by enterocytes into 
chylomicron particles. The structural protein of chylomicrons is ApoB48. Through RNA 
editing, the full-length ApoB100 protein is not expressed in the gut. Forty-eight percent of the 
sequence is translated due to a stop codon. The shortened ApoB48 lacks the C-terminal LDL-
receptor binding domain of ApoB100. Nascent chylomicrons, up to 1000 nm in diameter, are 
released in the lymphatic system and eventually enter the blood via the left thoracic duct. 
ApoCII in the chylomicrons activates lipoprotein lipase (LPL) when the particles arrive to 
capillaries [276]. LPL is synthesized in peripheral tissue such as skeletal muscles and adipose 
tissue. It hydrolyzes triglyceride-rich lipoproteins in the lumen of capillaries bound to 
glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 
(GPIHBP1) on the endothelial surface. This releases free fatty acids that are taken up by the 
adjacent tissue. The chylomicron particle continuously shrinks in size to become a remnant 
particle with a size of 30-50 nm. ApoCII dissociates from the particle, while Apolipoprotein 
E (ApoE) instead is acquired from plasma. ApoE mediates clearance of the chylomicron 
remnants by hepatocytes.  
During the fed state, chylomicron synthesis and LPL activity are high, as they are stimulated 
by insulin. This leads to storage of free fatty acids in the adipose tissue. In the fasted state, 
both chylomicron synthesis and LPL activity are low. The mobilization of stored triglycerides 
in the adipose tissue is mediated by adipose triglyceride lipase and hormone-sensitive lipase 
[277]. The liver has its specific hepatic lipase, which also hydrolyzes triglycerides and makes 
lipoprotein particles denser.  
1.3.1.2 Very low-density lipoproteins and low-density lipoproteins 
Hepatocytes repack cholesterol in VLDL particles that are secreted in circulation and 
distributed to muscles and adipose tissue. ApoB100 is the structural protein of these particles. 
Being 4563 amino acids long, it has an mRNA transcript larger than 14 kilobases [278]. 
 22 
Human livers express the full-length ApoB100 solely, while mice could have up to 65% 
edited mRNAs [279]. Microsomal triglyceride transfer protein allocates lipids to synthesized 
ApoB100 protein. The formed VLDL particles are 30-80 nm in diameter and rich in 
triglycerides. After secretion in the circulation, lipolysis shrinks the particle-size to form 
intermediate-density lipoprotein (IDL) particles. LDL particles are formed through the 
continued lipolysis in circulation. Other apolipoproteins, present in VLDL and IDL, 
dissociates from the particle, and makes ApoB100 the sole apolipoprotein of LDL. LDL is 
the main lipoprotein that delivers cholesterol to peripheral cells.  
The ApoB protein contributes to innate immunity through protecting against invasive 
Staphylococcus infections [280]. A peptide fragment derived from ApoB has also been 
identified to convey pro-inflammatory signals and trigger platelet activation [281, 282].  
1.3.1.3 High-density lipoprotein (HDL) 
Cholesterol is transported back to the liver through reverse cholesterol transport. ApoA1 is 
formed in the liver and secreted in the blood. In the periphery, ApoA1 docks to cholesterol 
exporters on cells, loads up with cholesterol, and transports it back to the liver. ABC 
transporter A1 (ABCA1) controls the rate-limiting step in HDL formation. It forms discoidal 
HDL, which is further loaded with intracellular lipids by ABCG1, and the particle reaches a 
spherical diameter size of 5-12 nm. The spherical change is mediated by lecithin-cholesterol 
acyl transferase that esterifies free cholesterol. Foam cells have their excessive cholesterol 
stored as esters in lipid droplets. The impaired cholesterol efflux of these cells can partly be 
due to inflammation [283]. 
The cholesterol that reaches the liver is directly secreted to the bile or metabolized to bile 
acids, and then secreted. This secretion is ABCG5/8-dependent. The bile is excreted in the 
small intestine. From there, cholesterol can either be reabsorbed or further excreted in the 
feces. The reabsorption pathway forms an enterohepatic cycle. The absorption of cholesterol 
from the gut is incomplete, and usually around 50% of the dietary cholesterol is excreted. 
Cholesterol-ester transfer protein (CETP) in the blood can shuffle cholesterol from HDL to 
other lipoproteins. This counteracts reverse cholesterol transport. Drugs that specifically 
inhibit CETP increase HDL-cholesterol, but do not reduce risk for cardiovascular events 
[284]. This has led to doubts whether raising HDL will ever translate into a therapy against 
cardiovascular disease in humans [285]. Another lipid transfer protein found in human 
plasma is phospholipid transfer protein (PLTP). It transfers phospholipids from triglyceride-
rich lipoproteins to HDL. By this, it regulates the HDL particle size. 
1.3.2 Regulation of lipid metabolism 
The liver is the main organ regulating lipid metabolism, accounting for around 70% of the 
LDL uptake from plasma. LDL receptors are, however, present on most cells, and mediate 
uptake through endocytosis of lipoproteins carrying ApoB100 or ApoE proteins [286]. LDL 
receptors are regulated by SREBPs. When SREBPs sense a lack of cholesterol in the cell 
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membrane, they translocate to the nucleus and activate gene transcription of LDL receptors 
and cholesterol synthesis-related genes [273]. The APOE gene is polymorphic and exists in 
three major alleles in humans, APOE2, APOE3, and APOE4. ApoE2 and ApoE4 proteins 
have lower affinity to the LDL receptor than ApoE3, leading to slower clearance of 
chylomicron remnants. Especially APOE4 is associated with hyperlipidemia and 
atherosclerosis development [287]. 
Other receptors important for hepatic uptake of LDL are low-density lipoprotein receptor-
related protein 1 (LRP1), VLDL-receptor, sortilin, and scavenger receptor B type I (SR-BI). 
LRP1 is ubiquitously expressed, although most abundant in vascular smooth muscle cells, 
hepatocytes, and neurons. It mediates endocytosis of ApoE-containing lipoproteins. The 
interaction also leads to cell signaling, mediating an anti-atherosclerotic effect in vascular 
smooth muscle cells by maintaining the vascular wall organization [288]. The VLDL receptor 
is another LDL receptor family member, but it is usually not present in the liver. In Paper II, 
we report an upregulation of the mRNA level in the liver of Ldlr-/- mice after depletion of 
Tregs. If this results in increased protein expression remains unknown. The main function of 
the VLDL receptor is to mediate uptake of ApoE-containing lipoproteins in the periphery.  
Sortilin is a multi-ligand receptor encoded by the SORT1 gene. In the liver, it targets pre-
secretory degradation of nascent VLDL particles. Reports have also indicated sortilin to 
function as a cell surface receptor that binds ApoB-containing lipoproteins [289]. The SORT1 
locus is strongly associated with serum lipoprotein levels as well as myocardial infarction in 
genome-wide association studies [290]. Heparan sulfate proteoglycans are present in the 
extracellular matrix and on the cell surface where they act as endocytosis receptors mediating 
uptake of various macromolecules, including lipoproteins. Syndecan-1 belongs to this family 
and clears ApoE-VLDL particles in the liver [291]. Yet another receptor that can mediate 
hepatic uptake of lipoproteins is SR-BI, mainly targeting HDL particles [292]. 
Proprotein convertase subtilisin/kexin 9 (PCSK9) is a serine protease that regulates recycling 
of LDL receptors. This is an interesting target for a new class of lipid-lowering drugs that 
increases the LDL receptors in the liver by inhibiting PCSK9. Gain-of-function mutations in 
the PCSK9 gene are described to cause autosomal dominant hypercholesterolemia [293]. 
PCSK9 is produced in the liver and secreted in the circulation. It binds to the LDL receptor 
and targets it for degradation, preventing its re-use and therefore lowers the total amount of 
receptors present on the cell surface. This reduces cholesterol uptake by the liver and thus 
increases plasma cholesterol. Monoclonal PCSK9 antibodies have shown notable lipid-
lowering effects with administration once per month [294].  
As discussed in the lipoprotein section, apolipoproteins are fundamental regulators of lipid 
metabolism. ApoCIII is an important component of ApoB-containing lipoproteins [295]. It 
blocks the clearance of triglyceride-rich lipoproteins, opposing the effects of ApoE.  
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1.3.2.1 Nuclear hormone receptors sensing lipids 
Liver X receptors (LXR) are important intracellular cholesterol sensors that regulate the 
cholesterol efflux pathway transcriptionally [296]. LXRs are activated by oxysterols. In 
macrophages, LXRs control reverse cholesterol transport and protect against foam cell 
formation. Activating these transcription factors inhibits inflammatory gene expression, 
mainly by negative regulation of NF-B. Synthetic LXR agonists can inhibit experimental 
atherosclerosis [297], but LXR activation also induces hypertriglyceridemia through effects 
on hepatocytes.  
Bile acid formation is controlled by the farnesoid X receptor (FXR). When FXRs sense a 
reduced return of bile from the gut, the enzyme, cholesterol 7 alpha-hydroxylase (CYP7A1) 
is activated and bile production is increased [298]. On the contrary, retinoid X receptors 
(RXR) can downregulate CYP7A1 and bile acid synthesis. RXRs also downregulate the re-
absorption of cholesterol in the gut. To make this regulation more intricate, LXRs, FXR, and 
RXRs form heterodimers to regulate transcription in response to their various ligands. 
Fatty acid metabolism is controlled by peroxisome proliferator-activated receptors (PPAR). 
They form heterodimers with RXRs and regulate gene transcription of key enzymes in fatty 
acid and triglyceride metabolism, e.g., LPL. Endogenous PPAR ligands are free fatty acids 
and eicosanoids. Three main forms exist, PPAR, PPAR and PPAR. They have slightly 
different roles with differences in tissue distribution. PPARis important in the liver and in 
muscles. The hypolipidemic fibrate drugs activate PPAR and affect a range of steps in the 
lipid metabolism through lowering LDL and triglycerides, but mainly by raising HDL by 
transcriptionally regulating ApoA1 [299]. These drugs are used as a complement to statins 
and have been shown to lower non-fatal myocardial infarctions, but not all-cause mortality 
[300].  
PPAR is important in adipocytes and controls lipid storage. Thiazolidinediones, more 
commonly known as glitazones, target and activate PPAR, which increases insulin 
sensitivity and lowers glucose levels. A common polymorphism in the PPARG gene 
decreases the risk of insulin resistance and protects against diabetes [301]. PPAR is also 
involved in cellular differentiation. It induces an alternatively activated macrophage 
phenotype that is anti-inflammatory and is involved in tissue repair. Agonists of PPAR and 
PPAR can limit experimental atherosclerosis though inhibition of foam cell formation [302]. 
PPARis expressed in many tissues. Agonists to PPARcan protect against experimental 
atherosclerosis through effects in macrophages and anti-inflammatory actions in 
atherosclerotic plaques [303]. 
1.3.2.2 Inflammatory-mediated regulation of lipid metabolism 
Inflammation is linked to metabolic disorders such as obesity, diabetes, and cardiovascular 
disease. Combinations of abdominal obesity, elevated blood pressure, raised plasma 
triglycerides, low HDL, and reduced glucose tolerance is diagnosed as metabolic syndrome, 
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which is associated with cardiovascular disease [304]. During evolution, immunity has 
developed to mount strong responses against pathogens. Metabolism has, at the same time, 
evolved to store surplus energy in adipose tissue for periods of starvation. In modern society, 
starvation and infections are lesser problems than they were during the early evolution of 
mankind. This provides grounds for inapt reactions by both the immune system and 
metabolism. 
Interestingly the fruit fly, Drosophila, has a common organ serving as adipose tissue, liver, 
and hematopoietic system [305]. Thus, there is an evolutionary link between the immune 
system and metabolism. A lot of immune cells still reside in the human liver, e.g., liver 
macrophages known as Kupffer cells, and during fetal life, hematopoiesis occurs here. The 
interconnections between inflammation and metabolism are crucial for the immune system to 
mobilize energy for its response during infections. All forms of inflammation increase energy 
expenditure. Conversely, malnutrition or overnutrition can cause aberrant immune responses. 
Infiltrations by immune cells are seen in the adipose tissue during obesity, and similar to 
cardiovascular disease, the metabolic syndrome is characterized by a local chronic 
inflammatory process with elevated systemic inflammation markers such as CRP [75].  
Hypertriglyceridemia is observed during acute infections [306]. The cytokine, TNF, 
mobilizes energy from adipose tissue and muscles, leading to cachexia, along with 
leukocytosis [307]. Initially, TNF was described to block the activity of LPL [308], but the 
functionality has been shown to be more complex [309]. Similar to TNF, 
lipopolysaccharides, and the inflammatory cytokines IL-1, and IL-6, increase plasma 
VLDL-triglycerides [309]. This is attributed to increased hepatic lipogenesis and reduced 
clearance by lower LPL activity. Specific induction of hepatic inflammation by activation of 
NF-B in hepatocytes has been shown to increase VLDL production [310].  
Mobilization of cholesterol is of less importance in acute inflammation, with accordingly 
smaller effects of inflammation on plasma cholesterol levels. Nonetheless, the cellular 
cholesterol content is important for rapidly proliferating cells, such as T cells, with their need 
to synthesize new cell membranes [311]. In addition to these effects, inflammation 
downregulates the cellular lipid sensors, RXRs, LXRs, and PPARs, thereby loosening the 
tight control of lipid metabolism [309].  
The effects on lipid metabolism by chronic inflammation are more complex. Dyslipidemia is 
often seen in rheumatoid arthritis, but several mechanisms are likely to contribute to the 
elevated cardiovascular risk in these patients [312]. Systemic lupus erythematosus is more 
distinctly associated with a pro-atherogenic lipid profile and with an elevation of VLDL 
levels [313]. Various TNF blocking drugs that are commonly used to treat rheumatoid 
arthritis have been shown to both increase and decrease plasma lipids [314]. The treatments 
are nonetheless efficient in reducing inflammation and patients with rheumatoid arthritis 
under treatment with these drugs have a lower incidence of cardiovascular events [315]. 
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Alterations of gut microbiota have been linked to metabolic syndrome, cardiovascular 
disease, and type 2 diabetes [2]. Gut microbiota promotes obesity through assisting intestinal 
uptake of nutrients and increasing LPL activity, which in turn cause triglyceride storage in 
adipose tissue [316]. At the same time, gut microbiota can reduce cholesterol absorption 
through a reduction in bile acid release [317]. This is achieved through FXR antagonism with 
subsequent CYP7A1 downregulation [318].  
Short-chain fatty acids, consisting of less than six carbon atoms, are important microbial 
products in the intestinal tract and can affect immune cells. Interestingly, Th1, Th17, and 
Treg cell differentiation is influenced by short-chain fatty acids [319, 320]. Moreover, gut 
microbiota can cause formation of trimethylamine-N-oxide in response to digestion of red 
meat [321]. This accelerates atherosclerosis and provides an explanation why red meat 
consumption is associated with cardiovascular disease. The increased atherosclerosis is 
suggested to be mediated by upregulated scavenger receptors on macrophages and impaired 
reverse cholesterol transport [321]. Diet, genetic factors, and the immune system can all 
influence the microbiome [2], and numerous mechanisms exist by which microbiota regulate 
host metabolism, reflecting its great diversity. 
In conclusion, the connections between immunity and metabolism are vast. Acute 
inflammation induces hypertriglyceridemia, but the effects of chronic inflammation on 
metabolism are unclear with several mechanistic links missing. The papers in this thesis 
illustrate how such links can be methodically explored in well-controlled in vivo models in 
conjunction with isolated in vitro systems. Translational approaches can further consolidate 
experimental findings. In this way, important crosslinks between immunity and metabolism 
could be identified. T cells orchestrate the immune system, but notions also suggest them to 
control metabolism [322]. Detailed mechanistic information on how various T cells affect 
lipid metabolism remains to be discovered, which in turn may unravel drug targets. A novel 
treatment that both decreases chronic vascular inflammation and corrects a perturbed lipid 
metabolism is likely to be useful to limit atherosclerosis and its devastating symptoms.  
Subendothelial retention of lipoproteins triggers the inflammatory process that leads to 
atherosclerotic plaque formation. T cells in the plaques perpetuate inflammation, but several 
questions regarding the pathogenesis of atherosclerosis remain to be clarified. The 
autoimmune component in the disease development is poorly understood, antibodies 
connected to the disease have unresolved actions, and the actual role for LDL-reactive T cells 
in atherogenesis needs to be defined. The investigation of these aspects possibly harbors 
unexpected therapy targets. For instance, T-helper cell subsets are suggested to have 
detrimental roles for plaque stability. Th1 cells promote lesion development and destabilize 
plaques. Circumstantial evidence in the literature suggests opposite effects by both Tregs and 
Th17 cells. A mechanistic understanding of these processes is needed to draw correct 
conclusions from such reports. In the future, this could hopefully lead to a specific treatment 
for stabilization of vulnerable plaques prone to rupture. 
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This thesis attempts to answer how different T-helper cell subsets affect atherosclerosis 
development and plaque composition. The papers included illustrate the roles that three 
separate T cell subsets — Th17, Treg, and Tfh cells — play in atherosclerosis development. 
All three subsets were surprisingly shown to have major impacts on lipid metabolism by 
separate mechanisms. 
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2 AIMS 
The studies included in this thesis aimed to investigate T-cell specificity and regulation in 
atherosclerosis.  
The specific aims were to: 
I. Investigate the effects of increased TGF- signaling in T cells on atherosclerosis. 
II. Define the role that Foxp3+ Tregs play in atherosclerosis. 
III. Examine the role that LDL-reactive T cells play in atherosclerosis. 
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 MOUSE MODELS 
C57BL/6 is the most commonly used inbred mouse strain to study atherosclerosis, and it is 
used as the genetic background for the majority of genetically modified strains [323]. This 
strain was established in the 1920’s [324], and its genome was published in 2002 [325], only 
one year after the human genome. Experiments in mouse models have several benefits. The 
colonies reproduce fast, housing is space-efficient, and inbreeding reduces experimental 
variability. The model also allows for genetic manipulations, such as targeted gene deletions 
and insertion of transgenes.  
C57BL/6 mice develop a Th1-biased immune response, while other mouse strains such as 
BALB/c are more Th2-prone. BALB/c mice are resistant to atherosclerosis, but if their 
immune response is Th1-skewed through genetic manipulation, atherosclerosis could be 
induced [326]. Wild-type mice, such as C57BL/6, are nonetheless relatively resistant to 
atherosclerosis. They have most of the circulating cholesterol in HDL, and complex 
atherosclerotic lesions are not formed even when fed a high-fat and high-cholesterol diet. 
Hyperlipidemic mice, such as Apoe-/- on the C57BL/6-background, are therefore used as 
experimental models of atherosclerosis [327]. The ApoE protein is mainly produced by 
hepatocytes and macrophages and is taken up by chylomicrons. The lack of ApoE impairs 
hepatic uptake of remnant particles and severely perturbs lipid metabolism. In Apoe-/- mice, 
circulating cholesterol is predominantly in VLDL particles, and the mice develop complex 
atherosclerotic plaques on a standard chow diet. ApoE is also involved in the development of 
myeloid cells [328], and since this may influence immune reactions, we chose to use Ldlr-/- 
mice for studies of atherosclerosis included in this thesis. 
Ldlr-/- mice mimic the development of atherosclerosis seen in humans with familial 
hypercholesterolemia (FH) [329]. The Ldlr-/- mice need a Western type diet to develop 
atherosclerosis [330]. The LDL receptor recognizes ApoB100 or ApoE and mediates uptake 
of LDL particles through endocytosis. As mentioned before, LDL receptors are fundamental 
for liver clearance of LDL from circulation. This makes bone marrow transplantation into 
Ldlr-/- recipients a useful tool in experimental atherosclerosis. The effect of the transplanted 
hematopoietic cells on atherosclerosis development can be assessed in the hyperlipidemic 
Ldlr-/- chimeras. 
Human APOB100-transgenic Ldlr-/- (HuBL) mice carry the full-length human APOB100 
gene [78, 331]. Codon 2153 of the APOB100 gene inserted in these mice has been converted 
from leucine to glutamine to prevent the formation of ApoB48 in the liver and gut [332]. 
Mice producing such humanized lipoproteins develop hypercholesterolemia and 
atherosclerosis on a standard chow diet, but the development of complex atherosclerotic 
plaques takes at least six months [333]. The development of hypercholesterolemia on a low-
fat diet is likely due to overexpression of human ApoB or decreased receptor-mediated 
uptake of the humanized particles. A large fraction of circulating plasma cholesterol is held in 
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LDL particles. This gives HuBL mice a more human-like dyslipidemic lipoprotein profile 
compared to Apoe-/- and Ldlr-/- mice. In addition, HuBL mice allow studies of human ApoB as 
an autoantigen, which may facilitate translation aspects of findings into human disease. 
The atherosclerosis-prone mouse strains mentioned above develop complex atherosclerotic 
plaques with shared features of human disease. However, the mouse models are fairly 
resistant to plaque rupture with ensuing myocardial infarction. Atherothrombosis is 
sporadically detected and experimentally challenging to assess [334-336]. Special models of 
plaque rupture have been developed, but the experimental field lacks a reliable and 
reproducible model for assessment of plaque stabilizing agents. 
To study T cells influenced by increased TGF- signaling, a mouse model that targeted the 
TGF--inhibitory molecule Smad7 was used. Through the Cre-lox technique, conditional 
gene deletions are possible. Specific recombination at LoxP-sites is induced by a Cre 
recombinase expressed under a tissue-specific promoter [337]. In the Smad7-flox mice, 
created for this project, the promoter, exon 1, and exon 2 of the Smad7 gene are flanked by 
LoxP-sites. Crossing the Smad7-flox strain with a CD4-Cre expressing mouse conditionally 
deletes the Smad7 gene in T cells. Bone marrow transplantation into Ldlr-/- mice was used to 
study atherosclerosis development [338]. The results are presented in Paper I. 
To study the effects of Foxp3+ Treg depletion, the DEREG (depletion of regulatory T cells) 
mouse model was employed. It expresses a fusion protein of the human diphtheria toxin 
receptor and enhanced green fluorescent protein (eGFP) under the control of the Foxp3 
promoter [339]. Bone marrow was transplanted into Ldlr-/- mice to study atherosclerosis 
development. Mice are naturally unaffected by diphtheria toxin [340]. A selective depletion 
of the human diphtheria toxin receptor-expressing Foxp3+ T cells was achieved through 
administration of diphtheria toxin. This does not affect CD25+ T effector cells, as CD25-
depleting antibodies do. CD25-depletions, which have been used to study Treg function 
[244], are therefore not optimal and do not reproduce the autoimmune phenotype seen in 
scurfy and DEREG mice [63, 339]. The results from the Foxp3+ Treg depletion in 
atherosclerosis are presented in Paper II. 
To investigate T-cell specificity in atherosclerosis, three new TCR transgenic strains were 
generated that were reactive to human LDL. Previously, a panel of T-cell hybridomas had 
been created from mice immunized with human LDL particles [211]. TCR cDNA was cloned 
from three of the hybridomas reactive to human LDL and ApoB100 protein. These TCRs 
were subcloned under the CD2 promoter and used for production of transgenic mice. The 
mice strains from these three hybridomas were named: BT1, BT2, and BT3 and all expressed 
the -chain TRBV31 together with the -chain TRAV12, 4, and 14, respectively. A 
population of around 8% TRBV31+ T-helper cells exists in wild-type mice. This should be 
compared to the population of over 90% TRBV31+ T-helper cells in the BT strains. Exposing 
the transgenic T cells to their antigen, human LDL, evoked a strong response with 
proliferation and IFN- secretion. The effect on atherosclerosis was assessed in Paper III.  
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Different diets were used to study atherosclerosis in the mouse models. Table 2 describes the 
main differences, with the “Standard American diet” used as an example of food 
consumption in the Western world [341]. The main dietary component that dictates 
development of atherosclerosis in Ldlr-/- mice is cholesterol content [342]. A 1.25% 
cholesterol diet was used to rapidly induce atherosclerosis in the bone marrow transplanted 
Ldlr-/- mice. In HuBL mice, 0.15% cholesterol diet was used to study atherosclerosis 
development. Mice used for breeding or used as cell donors were fed standard chow, a low-
fat diet that does not correspond to food intake by humans (Table 2). 
Table 2. Comparison of different diet compositions. 
Diet Energy 
(kcal/g) 
Carbohydrates 
(kcal %) 
Protein 
(kcal %) 
Fat   
(kcal %) 
Cholesterol 
(w/w) 
Nordic nutrition recommendations - 45-60 10-20 25-40 - 
Standard American diet 4.8 50 15 35 0.07% 
Standard chow 3.0 72 17 11 0.02% 
Western diet 3.7 41 16 44 0.15% 
High fat diet 4.5 40 20 40 1.25% 
3.2 EXPERIMENTAL METHODOLOGY 
Standard methods were used to assess T-cell phenotypes. T-cell proliferation was assessed as 
3H-thymidine incorporation and cytokine secretion was analyzed in supernatants. Flow 
cytometry analysis was used to discriminate between cell populations. Intracellular staining 
of transcription factors and cytokines was performed to separate T-helper cell lineages. 
Quantification of atherosclerosis was done at several locations in the vascular tree. Cross-
sections from the first millimeter of the aortic root were stained and used for quantification of 
atherosclerotic burden [343]. This method leaves several sections available for 
immunohistochemical evaluation of plaque composition [344]. En face preparations allow 
quantification of lipid-laden plaques in the rest of the aorta. Disease burden in the innominate 
artery can also be quantified by the use of carefully pinned specimens. Typically, only the 
aortic arch with branches was used for en face preparation, and the thoracic and abdominal 
parts were saved for RNA purification. 
Blood sampling was done through tail vein bleeds or post-mortem cardiac puncture. Since 
CRP is expressed at very low levels in mice and does not act as an acute phase reactant [345], 
serum amyloid A was used as an inflammation marker in the mice studies. Other cytokines 
were analyzed with enzyme-linked immunosorbent assay [346] or cytometric bead array. 
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LDL was prepared from plasma through a two-step ultracentrifuge purification, which 
isolates plasma lipoproteins with a density between 1.019 g/ml and 1.063 g/ml [347]. LPL 
activity was measured in post-heparin plasma. Heparin releases LPL to the blood through 
interference of LPL’s interaction with GPIHBP1. Lipoprotein production was assessed after 
inhibition of LPL with tyloxapol and subsequent measurements of plasma triglycerides. To 
distinguish chylomicron- from VLDL production, 3H-glycerol was injected intravenously 
simultaneously with an olive oil gavage with 14C-trioleate. Radioactivity from tritium in 
plasma was assessed as a measurement of VLDL particles assembled in the liver. 
Radioactivity from radiocarbon in plasma was assessed as a measurement of chylomicrons 
produced in the gut. 
3.3 BIOBANK OF HUMAN ATHEROSCLEROTIC PLAQUES 
The Biobank of Karolinska Endarterectomies (BiKE) was established in 2001 as a 
collaborative research effort between the vascular surgeons at Karolinska University Hospital 
and the Experimental cardiovascular research unit at Karolinska Institutet. The biobank 
consists of carotid plaques from patients undergoing carotid endarterectomies at Karolinska 
University Hospital [348]. Patients usually present themselves with symptoms such as minor 
stroke, transient ischemic attacks or amaurosis fugax, but also asymptomatic patients are 
operated. Carotid endarterectomy is recommended in cases with more than 70% stenosis as 
determined by ultrasonography. The atherosclerotic specimens were snap frozen, followed by 
RNA purification, and subsequent gene transcription analysis with chip arrays [349]. This 
biobank was interrogated to correlate mRNA levels in Paper I.  
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4 RESULTS AND DISCUSSION 
4.1 IL-17 STABILIZES ATHEROSCLEROTIC PLAQUES 
Paper I investigates the effect of increased TGF- signaling in T cells on experimental 
atherosclerosis using a genetically modified mouse model. The increased TGF- signaling 
was achieved through T-cell specific gene deletion of the signaling molecule Smad7, an 
intracellular inhibitor of TGF- signal transduction. This led to differentiation of naïve T-
helper cells into Th17 cells in the pro-inflammatory context of atherosclerosis (Fig. 2). IL-6 
mRNA was expressed in the aorta as a response to hyperlipidemia and innate immune 
activation. IL-6 protein was also found in the draining lymph nodes where the conversion to 
Th17 cells occurred. Since no upregulation of IL-6 mRNA was observed in these lymph 
nodes, a plausible explanation is that IL-6 is drained to this location from the atherosclerotic 
plaques. TGF- is abundantly available in the aorta [258], and TGF- and IL-6 jointly 
differentiated the naïve T cells into Th17 cells.  
 
Figure 2. Schematic illustration of an atherosclerotic plaque. Lipoproteins infiltrate the arterial wall and initiate 
an inflammatory response with IL-6 production. Dendritic cells take up antigens in the plaque and migrate to 
draining lymph nodes where they present antigens to naïve T cells. In the present study, the T cells had a genetic 
predisposition to increased TGF- signaling by the lack of the negative feedback molecule Smad7. Together 
with IL-6 present in draining lymph nodes of the aorta, the T cells differentiated into Th17 cells. These cells 
migrate back into the lesion where they secrete IL-17A that stimulates smooth muscle cells to produce collagen, 
thereby stabilizing the fibrous cap, which could prevent ruptures. 
A stable fibrous cap was formed on top of the atherosclerotic lesions, and this effect was 
linked to IL-17A. In human carotid plaques, associations between IL-17A and markers for 
stable plaques were found. We could further show that IL-17A directly stimulates collagen 
production in vascular smooth muscle cells. Low levels of IL-17A in serum are associated 
with recurrent myocardial infarctions [241]. This corroborates our findings and suggests that 
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IL-17A is important for plaque stability in clinical disease. New treatments that neutralize IL-
17A in conditions such as psoriasis might therefore be hazardous.  
When the inflammation resolves, wound healing is initiated. Re-organization of the tissue 
occurs by replacement of the immune cells with tissue-resident cells and extracellular matrix. 
Trapped immune cells, with a low migratory capacity, characterize the atherosclerotic plaque 
[88]. The resolution of inflammation is compromised, and wound healing is restricted to the 
build-up of a stable cap. Smooth muscle cells migrate to form a layer underneath the 
endothelium where they proliferate and produce collagen, mainly of types I and III. IL-17A 
stimulates this process with induction of collagen type I synthesis. This process reflects IL-
17A’s function to form granulomas around pathogens and confine infections spatially [350]. 
However, in some organs such as the liver, the fibrogenic properties of IL-17A could be 
detrimental [58]. Local fibrogenic effects are beneficial for the stability of atherosclerotic 
plaques, but therapeutic stabilization would need a highly specific drug target, since off-target 
effects, such as liver fibrosis, are not acceptable. The option of local delivery to vulnerable 
plaques could be a futuristic possibility. The currently used local delivery method with drug-
coated stents is not suitable. A major problem is restenosis after a percutaneous coronary 
intervention with placement of a stent. The desired effect is to inhibit smooth muscle cell 
proliferation in these cases, and IL-17A would probably do the opposite. 
The IL-17 signaling pathway is operative in several tissues, and many cell types express IL-
17 receptors. Downstream signaling includes general inflammation pathways such as 
mitogen-activated protein kinases [351]. Indeed, we demonstrated that extracellular signal-
regulated kinase inhibition led to reduced collagen synthesis. The transcriptional regulation is 
mainly mediated through CCAAT/enhancer-binding proteins. The potential for IL-17 as a 
plaque stabilizing therapy, with such broad actions, is small, sharing limitations with TGF-
, even though the fibrogenic signal strength is less. 
In Paper I, an interesting difference in lipoprotein metabolism was observed (Fig. 3). 
Increased amounts of chylomicron remnants were detected in postprandial plasma. LPL and 
hepatic lipase had normal activity, and the hypertriglyceridemia was lessened in the fasted 
state. This indicates that synthesis, rather than catabolism of triglyceride-rich lipoproteins, 
was mediating the effect. The phenotype presented itself only during the last weeks of the 
experimental period and was not a result of the increased IL-17A signaling, as neutralization 
of IL-17A indicated. Thus, the stabilization of the plaques with a thicker cap and more 
collagen was independent of the effect on chylomicrons. The phenotype is nonetheless 
interesting in regards to the selective deficiency of Smad7 in T cells. To evaluate the effect, 
further studies of cholesterol turnover, with a closer examination of bile-mediated triglyceride 
uptake, are needed. 
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Figure 3. Assessment of Chylomicron and VLDL production. In this experiment, LPL was inhibited by 
tyloxapol injected intraperitoneally, then the mice were injected with 3H-Glycerol intravenously and received a 
100 µl olive oil gavage with 14C-trioleate. (A) Total triglycerides were measured in plasma at baseline, and after 
30, 60, 90, 120, and 300 minutes. Open circles represent Ldlr-/- controls and closed circles Smad7-deficient bone 
marrow chimeras (n=5). (B) 3H radioactivity in plasma as a measurement of VLDL production by the liver 
(DPM=Disintegrations per minute). (C) Chylomicron accumulation in the plasma, measured as 14C radioactivity, 
derived from the trioleate in the olive oil gavage mixture.  
The initial hypothesis of the project postulated that Smad7-deficient T cells would increase 
Treg differentiation. However, raised Treg levels were not observed in the spleen of these 
animals. Smad-dependent signaling is not of major importance for thymic differentiation of 
natural Tregs [36]. Increased Foxp3 mRNA levels in inguinal lymph nodes suggested a minor 
induction of peripheral Tregs. This effect was not seen in the para-aortic lymph nodes. In this 
location, the augmented TGF- signaling in T cells led to Th17 cell differentiation. Th1 cell 
differentiation was at the same time impaired. A previous study has investigated the opposite 
conditions. Disruption of TGF- signaling in T cells induces Th1 cell differentiation and 
promotes atherosclerosis [257]. This experiment contrasts with the present study and sheds 
light over a possible equilibrium existing between Th17 cells and Th1 cells in regard to 
plaque stability. Th17 cells stabilize plaques, while Th1 cells do the opposite. 
4.2 REGULATORY T CELLS CONTROL LIPID METABOLISM 
In Paper II the role of Foxp3+ Tregs in atherosclerosis was assessed by depleting this cell 
type specifically (Fig. 4). This led to the development of large atherosclerotic plaques, but the 
plaques did not contain signs of increased inflammation and expansions of uncontrolled 
effector T cells as expected. The number of T cells per lesion area was similar to controls and 
both macrophages and APCs were decreased in the plaques in spite of an observed 
monocytosis in the blood. The large plaque size was linked to elevated plasma cholesterol in 
VLDL particles. This was further associated with a downregulation of sortilin in the liver. 
Sort1 expression, encoding sortilin protein, is negatively regulated by Atf3 [353], a 
transcription factor under inflammatory control. In the liver, a concomitant increase of TNF 
and IFN-, pro-inflammatory cytokines, was observed on the mRNA level. Sortilin acts as a 
lipoprotein-regulating receptor in the liver [289]. The decreased sortilin levels led to delayed 
clearance of VLDL particles that instead were deposited in the vessel wall. Thus, depletion of 
Tregs both contributes to hypercholesterolemia and atherosclerosis through its effects on 
VLDL turnover. The SORT1 locus has the strongest identified association with LDL-
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cholesterol in humans [354].  Pathways that increase sortilin expression in the liver could 
potentially be targeted as treatments for dyslipidemia. Possibly, an anti-inflammatory drug 
that affects the sortilin pathway in the liver would lower plasma VLDL-cholesterol, which 
may lead to decreased atherosclerosis.  
 
Figure 4. Schematic illustration of a Foxp3+ Treg that expresses a human diphtheria toxin receptor (DTR), 
which enables specific depletion of this cell type by administration of diphtheria toxin (DT). Tregs normally 
keep inflammation and autoreactive responses at bay. When depleted, the inflammation-responsive gene Atf3 
was upregulated in the liver causing downregulation of sortilin. Sortilin lowers plasma VLDL by acting as a 
receptor on the cell surface on hepatocytes and by decreasing release of nascent VLDL particles. The increase in 
plasma VLDL, mainly caused by delayed VLDL clearance, led to accelerated atherogenesis. The immune 
activation in the plaques was similar to controls, but the plaques had a large necrotic core with cholesterol 
crystals. Potentially, these large and lipid filled plaques are more vulnerable to rupture. In case of rupture, the 
blood comes in contact with thrombogenic material in the core and a thrombus forms that occludes the vessel. 
Interestingly, the delayed clearance of VLDL particles led to an increased activity of LPL and 
hepatic lipase. The lipase activity made the circulating VLDL particles triglyceride poor, 
which was reflected by a decrease in plasma triglycerides. Increased PLTP activity was also 
observed. PLTP shuffles phospholipids from VLDL to HDL, and a small increase of 
triglyceride-containing HDL particles was accordingly seen in the Treg depleted mice. How 
these factors contribute to atherogenesis in this model is unknown. The elevation of VLDL-
cholesterol was the main identified driving factor for atherosclerosis development in this 
model. This implicates that Tregs have an important role in controlling VLDL during 
homeostasis. The atherosclerosis process in Ldlr-/- mice is greatly influenced by VLDL-
cholesterol levels [355]. The use of this mouse model in the present study might exaggerate 
the impact that VLDL has on atherosclerosis. Additional atheroprotective mechanisms of 
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Tregs, apart from controlling lipid metabolism, could likely be identified in other models of 
atherosclerosis. Importantly, this study did not target antigen-specific Tregs that could have 
anti-inflammatory actions locally in the arterial wall. Overall, the actions of antigen-specific 
Tregs, such as LDL-reactive ones, remain to be elucidated and enhancements of their specific 
immune modulatory effects might be potential treatments for human disease. 
4.3 LDL-REACTIVE T CELLS LOWER PLASMA CHOLESTEROL 
In Paper III we could assess T-cell specificity in atherosclerosis by the use of three new 
TCR transgenic strains reactive to human LDL. Through crossbreeding to HuBL mice that 
express human APOB100, we examined the role of LDL-reactive T cells in atherosclerosis. 
The autoreactive and LDL-specific T cells were not completely deleted in the thymus, and 
some clones survived (Fig. 5). These cells assisted B cells that were reactive to LDL, which 
in turn, formed germinal centers, and produced anti-LDL antibodies. The antibodies formed 
immune complexes with LDL in the blood and increased lipoprotein clearance. This lowered 
plasma cholesterol levels and protected against atherosclerosis. Correlations between immune 
complexes, cholesterol, and lesion size suggested that these factors were dependent of each 
other. 
 
Figure 5. Schematic illustration depicting the thymus with its selection process to delete auto-reactive T-cell 
clones. Some ApoB-reactive T (BT) cells bypass the selection process and differentiate into Tfh cells in the 
spleen. The Tfh cells activate B cells reactive to LDL. In response to this, B cells form germinal centers and 
further differentiate into plasma cells. High-affinity anti-LDL IgG antibodies are secreted in the circulation, 
where the antibodies bind their antigen, LDL, forming immune complexes. This lowers LDL-cholesterol levels 
in plasma and protects from atherosclerosis. 
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Adoptive transfer experiments confirmed the notion of an atheroprotective humoral anti-LDL 
effect induced by LDL-reactive T cells. The injected CD4+ T cells differentiated into Tfh 
cells in the spleen. These LDL-specific Tfh cells induced a strong B-cell response with 
plasma cell differentiation and antibody production. The produced anti-LDL IgG antibodies 
formed immune complexes with circulating LDL particles and lowered plasma cholesterol 
levels. Transfer of plasma with high anti-LDL IgG titers from the injected mice could also 
induce increased LDL clearance in a separate batch of HuBL mice. 
The initial clearance of IgG-immune complexes is usually driven by Fc-dependent uptake in 
macrophages in the liver and spleen [356]. Hepatocytes could also directly bind IgG-immune 
complexes [357] and mediate the clearance of cholesterol seen in the present study, with 
excretion to the bile and gut. This pathway would be therapeutically interesting to explore. As 
more antigen-antibody complexes are formed, some of them are deposited in vascular beds, 
predominately in small arteries and renal glomeruli [1]. This activates the complement 
system, recruits neutrophils, and, as a consequence, leads to tissue damage. It is currently 
unknown if anti-LDL immune complexes induce any adverse effects. The main findings in 
our experiments were reduced plasma cholesterol levels and protection against 
atherosclerosis. 
In Paper III, we could show that ApoB is a tissue-restricted antigen with expression in the 
thymus, possibly controlled by AIRE or other means. To define precise mechanisms involved 
in the clonal deletion of ApoB-reactive T cells, the regulation of thymic APOB100 expression 
needs further evaluation. If ApoB expression were under AIRE-control, an interesting 
experiment would be to cross BT1xHuBL mice to AIRE-deficient animals. The negative 
selection of ApoB-reactive T cells would then be constrained from birth and onwards. 
Atherosclerosis development would unravel peripheral tolerance mechanisms or the lack 
thereof. Interestingly, the liver has a special role in peripheral tolerance and expression of 
proteins in the liver can by itself induce immunological tolerance [358]. Such tolerance to 
ApoB is seemingly not active in atherosclerosis with LDL-reactive T cells present in the 
plaques [156]. Speculatively, the local plaque environment breaks the tolerance to ApoB.  
Paper III uses TCR-transgenic mice with expression of a re-arranged TCR under control of 
the CD2-promoter. This infers some differences to the physiological clonal selection in the 
thymus [359]. Nonetheless, the use of this humanized mouse model identified important 
central tolerance to LDL. In a previous study, which corroborates our findings, the induction 
of neonatal tolerance to oxLDL led to clonal deletion of LDL-reactive T cells and reduced 
atherosclerosis development [360]. The central tolerance in the present study did not consist 
of a substantial induction of natural Tregs, and this might reflect the affinity of the 
investigated T-cell clone or the transgenic construct. Further studies are needed to clarify this 
notion. The adoptive transfers clearly suggested that induced LDL-specific Tregs play a 
minor role, judged by their low frequency. The main tolerance mechanisms identified were 
instead central clonal deletion and peripheral anergy. These mechanisms acted together with 
the humoral response to LDL to protect against atherosclerosis.  
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BCR activation is dependent on cross-linking several receptors on the B-cell surface. How 
this is achieved with ApoB as antigen is not known. LDL particles contain a single ApoB100 
molecule, and there is logically only one epitope per particle. This differs from the oxidation 
specific epitopes in the lipid moiety of LDL particles. A single epitope per particle would 
prohibit cross-linking of BCRs and clustering of receptors, important factors for the 
downstream signaling [361]. Particulate antigens are usually excellent for B-cell mediated 
antigen presentation, but an avidity threshold tightly regulates the BCR-mediated 
internalization [362]. Several epitopes per particle are needed to reach this threshold. 
Speculatively, aggregation and fusion of LDL particles are crucial to exceed the avidity 
threshold for BCR activation. Two LDL-aggregating enzymes are interesting in this context, 
phospholipase A2 and sphingomyelinase [79]. These enzymes are implicated in 
atherosclerosis both with activity in the vessel wall and by enhancing retention of lipoproteins 
by increasing proteoglycan binding [131, 363]. The present study provides clear in vivo 
observations of B-cell activation against ApoB100. The involvement of aggregated 
lipoproteins in this process is a highly interesting avenue for further investigations.  
4.4 CONCLUDING REMARKS 
Atherosclerosis is a chronic inflammatory disease containing both innate and adaptive 
immune reactions. The autoimmune component includes T cells that react to peptide 
fragments of ApoB100. During atherogenesis, T-cell activation leads to Th1 differentiation 
under the influence of pro-inflammatory mediators such as IL-12. Tolerance mechanisms, 
with induction of Tregs, are at the same time hampered. Under certain circumstances, 
differentiation into Th17 cells occurs by the influence of TGF- and IL-6. Effector T cells 
patrol the body and may undergo reactivation with cytokine production when they encounter 
their antigen in the plaques. Th1 cells contribute to destabilization of the plaques that make 
them vulnerable to rupture. On the other hand, Th17 cells promote plaque stability through 
IL-17A’s effects on smooth muscle cells and collagen synthesis. Tregs have an important role 
to control inflammation and autoimmune responses throughout the body. Uncontrolled 
inflammation in the liver leads to delayed lipoprotein clearance and dyslipidemia. A 
protective humoral immunity against LDL can counteract such deviations and lower plasma 
lipoprotein levels through antibody-mediated clearance of particles. This response requires 
help from LDL-reactive T cells. The role for these cells is therefore dual, both activating a 
pro-inflammatory response with perpetuation of the inflammation in the vessel wall as well as 
evoking a protective B-cell response in the spleen.  
LDL particles and inflammatory cells are major components of atherosclerotic plaques. 
Numerous interactions between lipoproteins and immune cells throughout the body may 
influence atherosclerosis development. This thesis gives three examples of the intricate 
interplay between the immune system and lipid metabolism: (I) Augmented TGF- signaling 
in T cells increases chylomicron levels, (II) Tregs regulate sortilin expression in the liver, and 
(III) anti-LDL antibodies mediate clearance of LDL. These interconnections should be 
interesting to explore further with a therapeutic objective. 
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Paper III provides unique insights into how LDL-reactive T cells act in atherosclerosis. 
Adoptive transfers identified differentiation into Tfh cells and unraveled a major 
atheroprotective humoral response with production of lipid-lowering antibodies. This effect 
has been observed in previous vaccination studies that induced LDL-reactive T cells, but 
been dependent on immunization protocols and other factors. When the effect has been 
observed, it has been downplayed. Importantly, vaccine adjuvants skew T-helper cell 
differentiation. We could monitor adoptively transferred T cells without such conditions. The 
BT1xHuBL cross in Paper III provided an unprecedented model system of LDL-
autoimmunity, and the protective anti-LDL humoral response was strong also in this model.  
Emerging evidence suggests that non-modified LDL could suffice for both innate and 
adaptive immune activation in atherosclerosis. The innate immune system could be activated 
by cholesterol crystals through inflammasome activation [135, 136], and by ApoB-derived 
peptides [281]. Similarly, the adaptive immune responses to LDL recognize native peptides 
from ApoB100 [155, 211]. In line with this, treatments that target modifications of LDL has 
so far been disappointing [132]. Nonetheless, there are factors that remain undetermined such 
as, how could native LDL activate B cells and why is cellular immune tolerance 
compromised in the atherosclerotic plaques? Further studies are needed to explore the 
possibility of local factors in the plaques that may mediate a break of tolerance. A window for 
oxidative modifications has been suggested in which LDL particles have pro-inflammatory 
properties, but still contain intact epitopes that activate LDL reactive T cells [80]. However, 
other LDL modifications might be of importance, e.g., aggregation of LDL for B-cell 
activation. ApoB-derived peptides are commonly presented by APCs [364], but under which 
conditions this lead to T-cell activation, pathogenic Th1 cell differentiation, or induction of 
anti-inflammatory Tregs remain to be determined.  
Cardiovascular disease is the main killer in the world, and new preventive measurements are 
required, e.g., a drug treating cardiovascular inflammation. The pathogenic inflammation in 
the vessel wall should be specifically targeted without affecting host defense or tumor 
surveillance. Targeting adaptive immunity with T-cell based treatments or vaccinations are 
attractive options [365]. The identification of disease-relevant epitopes in ApoB100 could 
open up possibilities for highly specific vaccine therapies. The properties of the epitopes will 
decide if therapies could be generalized or need to be personalized in accordance with HLA 
haplotype and other factors, which are, both genetic and environmental. As a start, the 
epitopes for the investigated TCR transgenic strains described in this thesis will be exactly 
mapped within the ApoB100 protein. 
As a final summary, this thesis provides mechanistic understanding of how three T-helper 
cell subsets indirectly counteract the Th1-driven inflammation in atherosclerosis: (I) Th17 
cells stabilize plaques, (II) Tregs control VLDL turnover, and (III) LDL-specific Tfh cells 
induce lipid-lowering antibodies. 
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